Q2 Earnings 2016

Full Text of English Language Coverage Below

1. Johnson & Johnson Raises Guidance, Buoyed by Pharma Growth

   Jul 19, 2016 | Wall Street Journal

   By Anne Steele and Jonathan D. Rockoff
   
   
   Johnson & Johnson on Tuesday raised its guidance for the year again as the health-care giant topped expectations in the latest quarter, helped by growth in its pharmaceutical business. The New Brunswick, N.J., company now expects earnings for the year of $6.63 to $6.73 a share, up from previous guidance for $6.53 to $6.68 a share.
2. Currency Pain Relief for Johnson & Johnson

   Jul 19, 2016 | Wall Street Journal

   By Charley Grant
   
   
   The strong-dollar problem for U.S. multinationals might, at long last, be fading away. That is one takeaway from Johnson & Johnson’s second-quarter results, out Tuesday. The health-care giant reported sales of $18.5 billion and adjusted earnings of $1.43 a share, beating analyst estimates. It also boosted full-year guidance on the top and bottom line.
3. J&J Raises 2016 Profit Forecast After Drug Sales Increase

   Jul 19, 2016 | Bloomberg

   By Jared S. Hopkins
   
   
   Johnson & Johnson increased its full-year profit and sales forecast after second-quarter profit topped analysts’ estimates, driven by growth in the pharmaceutical division, home to blockbuster products such as arthritis treatment Remicade.
4. Currency Pain Relief for Johnson & Johnson

   Jul 19, 2016 | Wall Street Journal

   By Charley Grant
   
   
   The strong-dollar problem for U.S. multinationals might, at long last, be fading away. That is one takeaway from Johnson & Johnson’s second-quarter results, out Tuesday. The health-care giant reported sales of $18.5 billion and adjusted earnings of $1.43 a share, beating analyst estimates. It also boosted full-year guidance on the top and bottom line.
5. Johnson & Johnson raises 2016 forecast, shares touch record high

   Jul 19, 2016 | Reuters

   By Natalie Grover and Susan Kelly
   
   
   Johnson & Johnson (JNJ.N) on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its prescription drugs business.
6. Johnson & Johnson tops 2Q forecasts despite profit drop

   Jul 19, 2016 | Associated Press

   By Linda A. Johnson
   
   
   Surging second-quarter sales of Johnson & Johnson's prescription drugs, its healthiest business, were more than offset by a one-time gain a year ago, driving profit down 11.5 percent. But the health care giant easily beat Wall Street's expectations and raised its full-year financial forecasts. Its shares rose to an all-time high Tuesday.
7. J&J jumps as drug sales power earnings

   Jul 19, 2016 | Financial Times

   By David Crow
   
   
   Johnson and Johnson published earnings that were ahead of Wall Street expectations after strong sales of new prescription drugs offset a lacklustre performance at its consumer health business. The world’s largest healthcare company posted adjusted earnings per share of $1.74, about 6 cents ahead what analysts were typically expecting, on revenues that were about $500m ahead of expectations at $18.5bn, reports David Crow in New York.
8. J&J CFO ‘Agnostic’ on Size of M&A, Looks at Deals in All Areas

   Jul 19, 2016 | Bloomberg

   By Cynthia Koons and Jared S. Hopkins
   
   
   Johnson & Johnson will consider deals of any size and for any of its three main businesses, chief financial officer Dominic Caruso said, though when it comes to pharmaceuticals the company is more interested in less-risky licensing agreements. “We’re equally interested in all three of our businesses,” Caruso said in an interview with Bloomberg News. “We’re agnostic whether it’s big or small.” That excludes a mega-merger with another drugmaker, he said.
9. Johnson & Johnson tops Wall Street forecasts

   Jul 19, 2016 | USA Today

   By Kevin McCoy
   
   
   Shares of Johnson & Johnson (JNJ) rose Tuesday after the U.S. healthcare giant reported second-quarter financial results that topped Wall Street estimates and raised its full-year financial guidance for 2016. The results were boosted by growth in the company's pharmaceuticals division that helped offset a decline in sales of consumer health products. Investors sent Johnson & Johnson shares up 2.97% to $123.14 in trading before U.S. financial markets opened.
10. Johnson & Johnson's stock surges after profit and sales beat, raised outlook

    Jul 19, 2016 | MarketWatch

    By Tomi Kilgore
    
    
    Johnson & Johnson's stock (JNJ) jumped 3.1% in premarket trade Tuesday, after the consumer and pharmaceutical products giant reported second-quarter profit and sales that beat expectations and raised its full-year outlook.
11. Johnson & Johnson crushed earnings expectations and raised its guidance for the year

    Jul 19, 2016 | Business Insider

    By Akin Oyedele
    
    
    Johnson & Johnson on Tuesday reported second-quarter profits that topped estimates, and raised its guidance for the rest of the year. The pharmaceutical giant posted revenues of $18.5 billion, up 3.9% year-on-year, and more than analysts’ median forecast for $18 billion according to Bloomberg.
12. Johnson & Johnson Lifts Full-Year Outlook as It Tops Quarterly Forecasts

    Jul 19, 2016 | MSN

    By Laura Board
    
    
    Johnson & Johnson on Tuesday posted second-quarter revenue and earnings that topped forecasts as its pharmaceuticals division continued to expand rapidly. The figures follow a forecast-busting first quarter, thanks also to strength in its pharmaceuticals business, and prompted the company once again to lift its full-year guidance. Johnson & Johnson shares had edged up 14 cents on Monday to $123.14. The stock has risen 27% in the past year. It was rising 3% in premarket trading on Tuesday.
13. Johnson & Johnson (JNJ) Beats on Q2 Earnings, Revenues

    Jul 19, 2016 | Zacks Equity Research

    Johnson & Johnson (JNJ - Analyst Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
14. Stocks Movements Activity: Johnson & Johnson (NYSE:JNJ) , Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE)

    Jul 19, 2016 | Street Updates

    By Eldred Matthew
    
    
    Johnson & Johnson (NYSE:JNJ) accumulated +0.11%, closing at $123.14 after floating between $122.44 and $123.22. The company has market capitalization of $338.71B. It has twelve month low of $81.79 and twelve month high of $124.30. The recent traded volume of 6.6 million shares lower than its average volume of 7.15 million shares. Analyst expected twelve month price target of $120.33.
15. Investors Cheer Johnson & Johnson's Q2 Results

    Jul 19, 2016 | Benzinga

    By R. Chandrasekaran
    
    
    Johnson & Johnson JNJ delivered solid results for the second quarter. The company reported 11.5 percent drop in net earnings despite sales witnessing 3.9 percent top line growth hurt by different expenses like restructuring. However, excluding adjustments, its profit would have increased 1.1 percent on YOY basis in the second quarter and came in well above the Street analysts' expectations.
16. Johnson & Johnson Q2 Results Top Estimates, Lifts FY16 Forecast

    Jul 19, 2016 | RTT News

    Healthcare major Johnson & Johnson (JNJ) reported Tuesday a decline in second-quarter profit mainly hurt by higher charges. Adjusted earnings topped analysts' estimates as sales also increased above market view. Further, the company lifted its fiscal 2016 earnings and sales forecast.
17. Johnson & Johnson (JNJ) Posts Earnings Results, Beats Expectations By $0.05 EPS

    Jul 19, 2016 | Sleek Money

    By Jamal Genner
    
    
    Johnson & Johnson (NYSE:JNJ) posted its earnings results on Tuesday. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.05. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion.
18. J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growth

    Jul 19, 2016 | Fierce Pharma

    By Tracy Staton
    
    
    Once again, Johnson & Johnson’s pharma engine powered top-line growth, with top performers Imbruvica, Xarelto and Daklinza all racking up impressive gains. Thanks to that “notable strength,” the healthcare giant hiked its sales and earnings forecasts for the year.
19. Shares of Johnson & Johnson (JNJ) Sees Large Inflow of Net Money Flow

    Jul 19, 2016 | Founders Daily

    By Don Renner
    
    
    Johnson & Johnson (JNJ) : Johnson & Johnson (JNJ) had a healthy money flow of $1.61 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $51.43 million, whereas, investors only sold shares worth $49.82 million on downticks. The stock closed the day with an up-down ratio of 1.03.The money flow in the block trades to the tune of $0.25 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $5.52 million worth of transactions were on upticks. A paltry $5.27 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 1.05. Johnson & Johnson (JNJ) stock slid $0.19 intraday and traded at 122.81, a change of -0.15% over previous days close. However, for the week, the company shares are -0.03% compared to previous weeks close.
20. Johnson & Johnson (JNJ) to Issue $0.80 Quarterly Dividend

    Jul 19, 2016 | Ambiente Ja

    By Adalberto Braga
    
    
    The company most recent volume stood at 7.19 million shares as compared to average volume of 7.16 million shares. The stock revealed the change of -0.15% with down momentum. The stock ended last trading session with the price almost 0.12 higher for the last 5 trading days, rebounding 53.68% from its 52-week low. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to "Sell", Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on April 20, 2016 to "Outperform", Firm has raised the Price Target to $ 125 from a previous price target of $122.Company shares were Reiterated by Piper Jaffray on April 20, 2016 to "Neutral", Firm has raised the Price Target to $ 106 from a previous price target of $105.
21. J&J quarterly sales rise 3.9 percent

    Jul 19, 2016 | Pop Herald

    By Vicki Perkins
    
    
    It has 1.86B of outstanding shares and its shares float measured at 1.19B. Johnson & Johnson (NYSE:JNJ): The stock opened at $123.77 on Friday but the bulls could not build on the opening and the stock topped out at $124.30 for the day.
22. Boulegeris Investments buys $12883389 stake in Johnson & Johnson (JNJ)

    Jul 19, 2016 | Nano News

    By Jack Bowen
    
    
    The company indicated that the stock would turn into ex-dividend on August 19. “Consensus does not fully recognize the value of the pipeline – we think the Street fails to capture much of the potential upside from the company’s pharmaceutical pipeline and line extensions”, analysts said in a note. Based on the most relevant historical data, there is a 53.85 percent probability for share price to go down following the next earnings report.
23. Jefferies Group Boosts Johnson & Johnson (JNJ) Price Target to $113.00

    Jul 19, 2016 | WKRB News & Analysis

    By Scott Davis
    
    
    Johnson & Johnson (NYSE:JNJ) had its price objective raised by Jefferies Group from $109.00 to $113.00 in a report issued on Thursday morning. The firm currently has a hold rating on the stock.
24. Johnson & Johnson Q2 Earnings, Guidance Beat (JNJ)

    Jul 19, 2016 | MSN

    By Richard Saintvilus
    
    
    Shares of Johnson & Johnson Corporation (JNJ) are rising about 1.5% higher in the Monday's early trading session after the global healthcare conglomerate reported second quarter fiscal 2016 earnings results that beat Wall Street's estimates. Combined with its upbeat outlook, the company's confidence not only implies market share gains it its pharmaceutical segment, but also affirms that its 20% year-to-date stock gains have been no fluke. (See also: Behind Johnson & Johnson's 91.5% Rise in 10 Years.)
25. Johnson & Johnson: JNJ Stock Looks Even Better After Earnings

    Jul 19, 2016 | Investor Place

    By Dan Burrows
    
    
    Johnson & Johnson (NYSE:JNJ) delivered Wall Street’s favorite earnings treat — a beat and raise quarter — setting JNJ stock up to build handsomely on what has already been an enviable year of gains. The diversified healthcare company’s pharmaceutical segment was the standout driving top-line growth. Thanks to JNJ’s Imbruvica cancer drug, Xarelto blood thinner and Remade — an arthritis drug and J&J’s biggest seller — JNJ pharma sales rose almost 9% to $8.7 billion. Remicade sales rose 6.7% to $1.78 billion alone.
26. Johnson & Johnson's Unstylish Sprawl Looks Good

    Jul 19, 2016 | Bloomberg Gadfly

    By Max Nisen
    
    
    Conglomerates are out of style -- particularly in health care, which has seen a decade of spinoffs, sales, and asset swaps aimed at greater focus. Johnson & Johnson has bucked that trend, even as some of its units have struggled. But sometimes being out of step is the right move.
27. Johnson & Johnson Keeps Growing on Pharma Strength

    Jul 19, 2016 | The Motley Fool

    Healthcare giant Johnson & Johnson (NYSE:JNJ) has been a household name for decades, with mainstays like Band-Aid and Tylenol helping to drive consumer awareness of the company's extensive product list. Yet the consumer segment is now Johnson & Johnson's smallest in terms of sales, and the conglomerate's efforts to expand in the pharmaceutical and medical device arena have been vital to the company's overall success. Coming into Tuesday's second-quarter financial report, J&J investors were somewhat concerned that the company wouldn't be able to keep its bottom line moving upward. However, its results quashed those concerns and showed signs of life in some of the most challenging areas for J&J recently.
28. Jim Cramer — J&J Is an Absolutely Terrific Stock

    Jul 19, 2016 | The Street

    By Bret Kenwell
    
    
    Shares of Johnson & Johnson (JNJ) are up 1.6% Tuesday after the drug and consumer products company topped earnings per share and revenue expectations. A sub-2% gain may not seem impressive but for a stock that's already rallied some 25% over the past year, how much more can be expected? This quarter justifies that big rally, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment.
29. Johnson & Johnson (JNJ) CFO Caruso Is 'Very Happy With Results' He Tells CNBC

    Jul 19, 2016 | The Street

    By Giovanni Bruno
    
    
    Johnson & Johnson (JNJ) reported its second quarter earnings Tuesday morning and the results were better than anticipated. The company's adjusted earnings per share exceeded expectations coming in at $1.74, above the the forecast of $1.68. The company posted revenue of $18.5 billion, up 3.9% year-on-year, also better than what most analysts predicted, which was around $18 billion, according to Bloomberg.
30. J&J reports high sales growth despite increased litigation cost

    Jul 19, 2016 | BioPharma

    By Edwin Lopez
    
    
    Johnson & Johnson's pharmaceutical worldwide sales increased by 8.9% in the second quarter compared to a year prior, with $8.7 billion in overall sales. U.S. pharmaceutical revenue jumped higher, growing by 13.2%, while international sales growth was more muted.
31. Johnson & Johnson (JNJ) Stock Rises, CFO Talks M&A

    Jul 19, 2016 | The Street

    By Annie Palmer
    
    
    Shares of Johnson & Johnson (JNJ) are climbing 1.75% to $125.27 in afternoon trading today as the New Brunswick, NJ-based medical and pharmaceutical manufacturer's CFO Dominic Caruso says the company is considering mergers, Bloomberg reports.
32. Drug Group Lifts J&J; Shares Still Overvalued

    Jul 19, 2016 | Morningstar

    By Damien Conover
    
    
    Driven largely by outperformance in its drug group, Johnson & Johnson (JNJ)reported second-quarter results exceeding both our and consensus expectations, and we plan to slightly raise our fair value estimate. Nevertheless, we continue to view the stock as slightly overvalued, with increasing concerns for generic or biosimilar competition for complex drugs Concerta, Invega Sustenna, Risperdal Consta, and Remicade, which collectively represent over $10 billion in annual sales. Despite these concerns, we remain confident in the company’s wide moat, driven by steady innovation in the drug and device group coupled with solid brand power in the consumer group.
33. J&J Climbs on 2Q Earnings Beat

    Jul 19, 2016 | The Street

    By Alicia McElhaney
    
    
    Johnson & Johnson (JNJ) share prices reached new heights Tuesday morning after reporting better-than-expected second quarter earnings. Shares in the pharmaceutical company, which has a market cap of $343.7 billion, hit $127, an all time high, in pre-opening trading Tuesday, after its reported earnings per share of $1.74 beat Wall Street's consensus estimate by six cents. The stock fell back to $124.54 by mid-morning, though it was still up approximately 1% from the market's open.
34. Johnson & Johnson (JNJ) Hits New 52-Week High on Strong Earnings

    Jul 19, 2016 | American Banking and Market News

    Johnson & Johnson (NYSE:JNJ) shares hit a new 52-week high on Tuesday following a stronger than expected earnings report. The company traded as high as $125.75 and last traded at $125.10, with a volume of 6,491,292 shares trading hands. The stock had previously closed at $123.14.
35. Can Johnson & Johnson Keep Soaring Higher?

    Jul 20, 2016 | TheStreet

    By Gary Morrow
    
    
    Shares of Johnson & Johnson ( JNJ) reached new all-time highs yesterday with the help of a 1.7% surge. This earnings-inspired rally extends the stock's powerful post-Brexit rebound to just over 8.5%.
36. Johnson & Johnson (JNJ) Broke Out To A New High After Q2 Earnings Beat

    Jul 20, 2016 | RTT News

    Johnson & Johnson (JNJ) reported second quarter adjusted EPS of $1.74 Tuesday morning, up from $1.71 last year. Analysts expected EPS of $1.68. The company also increased its full year adjusted EPS forecast to between $6.63 and $6.73, from prior expectations of $6.53 to $6.68. Street expectations are for EPS of $6.61.
37. Johnson & Johnson Boosts Dow, Netflix Pressures the S&P 500

    Jul 20, 2016 | Keris Alison Lahiff

    By Keris Alison Lahiff
    
    
    It was the tale of two earnings seasons on Tuesday and Wall Street was stuck in the middle. While better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record, disappointment over Netflix pushed the S&P 500 and Nasdaq into the red.
38. Johnson & Johnson Hits Record High Despite Declines in Baby Care

    Jul 19, 2016 | TheStreet

    By Alicia McElhaney
    
    
    Johnson & Johnson share prices reached new heights Tuesday morning after reporting better-than-expected second quarter earnings.
39. Johnson & Johnson has reported second-quarter net income of $US4 billion

    Jul 20, 2016 | AAP

    The New Brunswick, New Jersey-based company said it had profit of $US1.43 per share. Earnings, adjusted for non-recurring costs and amortisation costs, came to $US1.74 per share. The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $US1.67 per share.

Television Coverage

40. CNBC Squawk Box

    Jul 19, 2016 | CNBC Squawk Box

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23502590?token=03bbf64d-6306-4800-9204-97f1989fffcd (1 minute 21 seconds)
41. Bloomberg Surveillance Video Clip

    Jul 19, 2016 | Bloomberg Surveillance

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23502603?token=03bbf64d-6306-4800-9204-97f1989fffcd (58 seconds)
42. Dominic Caruso Squawk Box Video Clip

    Jul 19, 2016 | CNBC Squawk Box

    View Clip Here: http://app.criticalmention.com/app/#/report/d58397c4-b79a-4310-9849-59492113ecbd (4 minutes 34 seconds)
43. Bloomberg GO Dominic Caruso Video Clip

    Jul 19, 2016 | Bloomberg GO

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23503029?token=03bbf64d-6306-4800-9204-97f1989fffcd (7 minutes 11 seconds)
44. Jim Cramer Squawk on the Street Video Clip

    Jul 19, 2016 | CNBC Squawk on the Street

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23504549?token=03bbf64d-6306-4800-9204-97f1989fffcd (2 minutes 4 seconds)
45. Bloomberg Markets Europe Video Clip

    Jul 19, 2016 | Bloomberg Markets (Europe)

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23507632?token=03bbf64d-6306-4800-9204-97f1989fffcd (20 seconds)
46. NJTV News With Mary Alice Williams Video Clip

    Jul 19, 2016 | NJTV News With Mary Alice Williams

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23522914?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04 (27 seconds)
47. Mad Money Jim Cramer Video Clip

    Jul 19, 2016 | Mad Money

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523048?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04 (24 seconds)
48. WNET Nightly Business Report (PBS NY) Video Clip

    Jul 19, 2016 | WNET Nightly Business Report (PBS NY)

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523119?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04 (54 seconds)
49. Capital Connection Video Clip

    Jul 20, 2016 | Capital Connection

    Capital Connection April 20, 2016 View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523591?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04 (28 seconds)
50. Squawk on the Street Video Clip

    Jul 20, 2016 | Squawk on the Street

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523682?token= (33 seconds)

Full Text of English Language Coverage Below

1. Johnson & Johnson Raises Guidance, Buoyed by Pharma Growth

   Jul 19, 2016 | Wall Street Journal

   By Anne Steele and Jonathan D. Rockoff

   Johnson & Johnson on Tuesday raised its guidance for the year again as the health-care giant topped expectations in the latest quarter, helped by growth in its pharmaceutical business.
   

   The New Brunswick, N.J., company now expects earnings for the year of $6.63 to $6.73 a share, up from previous guidance for $6.53 to $6.68 a share. It also raised its revenue forecast to a range from $71.5 billion to $72.2 billion, up from $71.2 billion to $71.9 billion. In April the company beat earnings expectations for the first quarter and raised its revenue and earnings guidance for the year.

   Chief Executive Alex Gorsky expressed optimism about J&J’s outlook, saying longstanding efforts to reshape the company’s struggling medical-device and consumer-health businesses were bearing fruit. He said J&J was positioned to surpass the world-wide health-care market’s current 3% to 5% annual growth rate.

   But J&J faces the threat of lower-priced competition emerging for some top-selling prescription drugs. And with about half of its sales overseas, J&J’s results have been pressured lately by a strengthening U.S. dollar and weakness in some emerging markets.

   Chief Financial Officer Dominic Caurso said during a conference call that J&J, which gets about 3% of its sales from the United Kingdom, is watching events in the country following its recent vote to leave the European Union.

   J&J’s pharmaceutical business, the company’s largest, continued to propel the company. Prescription-drug sales grew 8.9% to $8.65 billion.

   Executives attributed the growth to sales from new products, including blood-cancer drug Imbruvica, blood thinner Xarelto, multiple myeloma drug Darzalex, Type 2 diabetes treatments Invokana and Invokamet, and prostate-cancer drug Zytiga.

   Mr. Caruso said J&J doesn’t expect biosimilar competition this year for top-selling drugs Remicade and Procrit.

   Other J&J businesses, however, didn’t perform as well. In the second quarter, sales of J&J consumer health products slipped 1.8% to $3.42 billion, largely due to Venezuela’s devaluation of its currency.

   To bolster the consumer business, J&J has been doing deals, most recently a $3.3 billion purchase of privately held hair-product maker Vogue International LLC.

   Meanwhile, J&J’s medical device sales edged up just 0.8% to $6.41 billion.

   The medical-device business used to be J&J’s largest, but it has stumbled amid pricing pressures, increased competition and market changes. In response, J&J has exited certain areas, rejiggered how it sells devices and focused on high-growth categories like robotics and staplers. In January, J&J announced plans to cut about 3,000 jobs in its medical-devices division, or about 2.5% of the company’s total workforce.

   In all for the quarter ended June, earnings fell to $3.99 billion, or $1.43 a share, from $4.52 billion, or $1.61 a share, in the same period last year. Excluding certain items, adjusted earnings rose to $1.74 a share. Revenue ticked up 3.9% to $18.5 billion. Unfavorable currency rates shaved 1.4% off the latest quarter’s total.

   Analysts had projected earnings of $1.68 a share on $17.97 billion in revenue, according to Thomson Reuters.

   Shares, up 20% this year, rose 1.3% on the New York Stock Exchange in trading Tuesday morning.

   Return to headline | Return to top

2. Currency Pain Relief for Johnson & Johnson

   Jul 19, 2016 | Wall Street Journal

   By Charley Grant

   The strong-dollar problem for U.S. multinationals might, at long last, be fading away.

   That is one takeaway from Johnson & Johnson’s second-quarter results, out Tuesday. The health-care giant reported sales of $18.5 billion and adjusted earnings of $1.43 a share, beating analyst estimates. It also boosted full-year guidance on the top and bottom line.

   Strong results in the pharmaceuticals business helped propel growth. Cancer-drug sales, for instance, were up nearly 30% year over year, thanks in part to product launches. Pharmaceutical sales helped make up for sluggish growth in the medical-device business and falling sales in the consumer unit.

   Beyond the pharma performance, there is reason to be hopeful that significant headwinds have faded. The WSJ Dollar Index is down 1% over the past year after rising 35% over the past five.

   Currency translation reduced reported sales by 1.4%. That is the mildest hit to the top line in nearly two years. A year ago, currency-translation effects lowered revenue nearly 8%. Finance chief Dominic Caruso said on Tuesday’s analyst call that investors can expect a 1% hit to third-quarter sales at current spot rates.

   A moderation of foreign-currency pressures is good news for J&J since it books a majority of its sales overseas. It also bodes well for other health-care multinationals as they prepare to report earnings. Merck and Pfizer, for example, booked 52% and 49% of their sales overseas in the first quarter.

   And should the dollar weaken further, that could make all the difference for investors in a low growth environment that prizes safety.

   Return to headline | Return to top

3. J&J Raises 2016 Profit Forecast After Drug Sales Increase

   Jul 19, 2016 | Bloomberg

   By Jared S. Hopkins

   Johnson & Johnson increased its full-year profit and sales forecast after second-quarter profit topped analysts’ estimates, driven by growth in the pharmaceutical division, home to blockbuster products such as arthritis treatment Remicade.

   The shares rose 3.1 percent to $127 at 7:18 a.m. in New York, before the markets opened. The stock has been trading at all-time highs as J&J relies on prescription medicines like Remicade and psoriasis drug Stelara to drive sales and stem a slowdown from the medical devices division. Remicade accounted for about 20 percent of drug revenue for the New Brunswick, New Jersey-based company last quarter.

   The world’s biggest maker of health-care products raised its earnings forecast to $6.63 to $6.73 a share, excluding some items, from $6.53 to $6.68 previously. Analysts anticipated $6.61.

   In the second quarter, earnings were $1.74 a share, excluding some items, compared with the $1.68 average of 20 predictions compiled by Bloomberg. Drug sales increased 8.9 percent during the period, helping offset a decline in consumer products, while revenue from medical devices were little changed.

   Here are the highlights for the second-quarter:

   Sales were up 3.9 percent to $18.5 billion. Analysts anticipated $18 billion.

   Net income declined 11 percent to $4 billion, or $1.43 a share, from $4.52 billion, or $1.61 a share

   Drug sales:

   Remicade $1.78 billion vs estimate $1.71 billion
   Stelara $804 million vs estimate of $699 million
   Zytiga $601 million vs estimate of $551.3 million
   Xarelto $594 vs estimate of $563.5 million

   Sales at the consumer business – which includes Johnson’s baby-care products, Neutrogena and Listerine - fell 1.8 percent from the previous year. The company’s medical device sales increased by 0.8 percent versus the previous year.

   J&J’s shares have almost doubled since the start of 2010 as its drug division sales grew 9 points to 45 percent of revenue. The company has topped earnings estimates every period since the 2010 fourth quarter.

   Return to headline | Return to top

4. Currency Pain Relief for Johnson & Johnson

   Jul 19, 2016 | Wall Street Journal

   By Charley Grant

   The strong-dollar problem for U.S. multinationals might, at long last, be fading away.

   That is one takeaway from Johnson & Johnson’s second-quarter results, out Tuesday. The health-care giant reported sales of $18.5 billion and adjusted earnings of $1.43 a share, beating analyst estimates. It also boosted full-year guidance on the top and bottom line.

   Strong results in the pharmaceuticals business helped propel growth. Cancer-drug sales, for instance, were up nearly 30% year over year, thanks in part to product launches. Pharmaceutical sales helped make up for sluggish growth in the medical-device business and falling sales in the consumer unit.

   Beyond the pharma performance, there is reason to be hopeful that significant headwinds have faded. The WSJ Dollar Index is down 1% over the past year after rising 35% over the past five.

   Currency translation reduced reported sales by 1.4%. That is the mildest hit to the top line in nearly two years. A year ago, currency-translation effects lowered revenue nearly 8%. Finance chief Dominic Caruso said on Tuesday’s analyst call that investors can expect a 1% hit to third-quarter sales at current spot rates.

   A moderation of foreign-currency pressures is good news for J&J since it books a majority of its sales overseas. It also bodes well for other health-care multinationals as they prepare to report earnings. Merck and Pfizer, for example, booked 52% and 49% of their sales overseas in the first quarter.

    And should the dollar weaken further, that could make all the difference for investors in a low growth environment that prizes safety.

   Return to headline | Return to top

5. Johnson & Johnson raises 2016 forecast, shares touch record high

   Jul 19, 2016 | Reuters

   By Natalie Grover and Susan Kelly

   Johnson & Johnson (JNJ.N) on Tuesday raised its full-year 2016 sales and earnings forecasts and reported quarterly results that beat estimates, helped by strength in its prescription drugs business.

   Shares of the diversified healthcare products maker rose 1.6 percent at $125.06 on the New York Stock Exchange after touching a new record high of $125.75.

   Analysts said the overall results bode well for J&J shares. "... We expect today's results to drive further upside and, given investor preference for safer names with good dividend yields in the current market environment, we think it bodes well for the stock over the near term,” said Credit Suisse analyst Vamil Divan.

   Strong demand for the company's Imbruvica cancer drug and Xarelto blood thinner boosted pharmaceutical sales, which jumped 8.9 percent to $8.7 billion in the quarter. Sales of autoimmune drug Remicade, J&J's biggest product, rose 6.7 percent to $1.78 billion.

   The company, which is the first major U.S. drugmaker to announce quarterly earnings, raised its 2016 sales forecast to a range of $71.5 billion to $72.2 billion, from $71.2 billion to $71.9 billion previously.

   J&J expects sales to grow at a faster rate than the global healthcare market, which it sees increasing by 3 percent to 5 percent annually over the next five years, Chief Executive Officer Alex Gorsky said on a conference call.

   The maker of a variety of products from Tylenol to Band-Aid bandages to Acuvue contact lenses also increased its adjusted profit range to $6.63 to $6.73 per share, from $6.53 to $6.68.

   Investors have been concerned about potential competition to Remicade in the United States. U.S regulators earlier this year approved Inflectra, a cheaper version developed by Celltrion Inc (068270.KQ) and Pfizer Inc (PFE.N), but a patent battle between J&J and Celltrion has delayed its introduction.

   J&J said its sales outlook assumes no new U.S. competition for Remicade in 2016.

   New Jersey-based J&J is also restructuring its medical device business to focus on areas such as artificial knees and devices for trauma surgery.

   Worldwide device sales inched up about 1 percent to $6.4 billion in the quarter, buoyed by higher demand for its advanced surgery products. Growth in its devices business was roughly in line with the market, the company said.

   Total revenue rose 3.9 percent to $18.5 billion.

   Net earnings fell to $3.997 billion, or $1.43 per share, from $4.516 billion, or $1.61 per share.

   Excluding special items, J&J earned $1.74 per share.

   Analysts, on average, expected profit of $1.68 per share on revenue of $17.98 billion, according to Thomson Reuters I/B/E/S.

   Up to Monday's close, J&J's stock had gained about 20 percent this year.

   Return to headline | Return to top

6. Johnson & Johnson tops 2Q forecasts despite profit drop

   Jul 19, 2016 | Associated Press

   By Linda A. Johnson

   Surging second-quarter sales of Johnson & Johnson's prescription drugs, its healthiest business, were more than offset by a one-time gain a year ago, driving profit down 11.5 percent.

   But the health care giant easily beat Wall Street's expectations and raised its full-year financial forecasts. Its shares rose to an all-time high Tuesday.

   Sales of several key new medicines buoyed revenue, and medical device sales edged up. But sales dipped for consumer products such as Band-Aids and Johnson's Baby Powder. More importantly, J&J's top-selling prescription drug is facing cheaper competition, possibly as soon as this year, depending on the outcome of litigation.

   Remicade, an injected biologic drug for immune disorders including rheumatoid arthritis, already has competition in some other countries from "biosimilar" versions, near-copies of complex biologic drugs manufactured in living cells. Higher U.S. sales offset an overseas decline and boosted total Remicade sales to nearly $1.8 billion in the second quarter. As biosimilars reach the market in the U.S. and additional countries, total sales are expected to fall.
   

   The world's biggest maker of health care products reported net income of $4 billion, or $1.43 per share. That was down from $4.52 billion, or $1.61 per share, a year ago when the company had a $931 million gain from the sale of rights to pain drug Nucynta. J&J also took a $557 million charge for litigation costs in the latest quarter.

   Adjusted for one-time items, earnings came to $1.74 per share, 7 cents more than analysts expected.

   The New Brunswick, New Jersey-based company posted revenue of $18.48 billion in the period, up 3.9 percent and well above Street forecasts for $17.89 billion.

   Shares were up $2.14, or 1.7 percent, at $125.38 in afternoon trading after peaking earlier at an all-time high of $125.47.

   Analyst Jeffrey Loo at S&P Capital Global Market Intelligence kept his"Buy" recommendation on J&J and raised his 12-month target price for its shares by $10, to $143. He wrote that he expects growth in consumer sales in the second half and is "encouraged by the improvement" in medical devices.

   Credit Suisse analyst Vamil K. Divan wrote to investors that the "strong quarter" was driven by better-than-expected revenue in the prescription drug business, "with almost all of the key growth drivers delivering," and in the medical devices business, which is being reorganized due to slumping profits.

   The company said the strong dollar, which reduces the value of products bought overseas in local currencies, lowered sales by 2.7 percent. Such unfavorable exchange rates have been hurting U.S.-based multinational companies for the last few years, but by much more until recently.

   Johnson & Johnson raised its full-year earnings forecast to a range of $6.63 to $6.73 per share, up from its April forecast for $6.53 to $6.68 per share. It now expects revenue of $71.5 billion to $72.2 billion, up from $71.2 billion to $71.9 billion.

   "Our second-quarter results have continued the momentum that began with our first quarter," CEO Alex Gorsky told analysts during a conference call.

   Sales of prescription drugs, J&J's largest business, climbed 8.9 percent to $8.65 billion in the quarter, mostly due to a 13.2 percent jump in U.S. sales. Those increases were mainly driven by surging sales of newer medicines, including Imbruvica for blood cancer, type 2 diabetes pill Invokana, Darzalex for the bone marrow cancer multiple myeloma and heavily advertised Xarelto, for preventing heart attacks and strokes.

   Combo diabetes pill Invokamet won U.S. approval during the quarter and three medicines were approved for sale in the European Union.

   Sales of medical devices and diagnostics dipped nearly a percent to $6.41 billion, partly due to last year's sale of the Cordis heart devices unit. Gorsky noted J&J saw increases around 3 percent in the latest quarter in hospital admissions and procedures, which boosts sales for that business and some of its medicines.

   Sales of consumer health products dipped 1.8 percent to $3.42 billion, despite strong sales from pain relievers Tylenol and Motrin and skin care lines Aveeno and Neutrogena. On Monday, J&J closed a $3.3 billion acquisition of hair and personal products maker Vogue International LLC, and during the second quarter, it bought "dermocosmetics" maker NeoStrata Co. Inc.

   
   

   
   

   
   

   Return to headline | Return to top

7. J&J jumps as drug sales power earnings

   Jul 19, 2016 | Financial Times

   By David Crow

   Johnson and Johnson published earnings that were ahead of Wall Street expectations after strong sales of new prescription drugs offset a lacklustre performance at its consumer health business.

   The world’s largest healthcare company posted adjusted earnings per share of $1.74, about 6 cents ahead what analysts were typically expecting, on revenues that were about $500m ahead of expectations at $18.5bn, reports David Crow in New York.

   Shares in J&J jumped more than 3 per cent in pre-market trading on the news.

   J&J’s share of sales of Imbruvica, a cancer drug which it is co-developing with AbbVie, almost doubled year-on-year to $295m, while revenues from other recently-launched products were also strong.

   Robust US sales of Remicade, the company’s blockbuster arthritis drug, more than offset a 23.2 per cent decline in exports, which have been hit by the introduction of a copycat “biosimilar” version in Europe. Overall sales of the anti-inflammatory drug were $1.78bn versus $1.67bn a year ago.

   However, the company’s consumer division continued to struggle, with babycare sales falling 8 per cent from a year ago to $500m and wound care products like Band Aids falling by 25 per cent to $272m.

   Market had forecast revenues of $17.98bn and adjusted net income of $4.671bn or $1.68 a share.

   Return to headline | Return to top

8. J&J CFO ‘Agnostic’ on Size of M&A, Looks at Deals in All Areas

   Jul 19, 2016 | Bloomberg

   By Cynthia Koons and Jared S. Hopkins

   Johnson & Johnson will consider deals of any size and for any of its three main businesses, chief financial officer Dominic Caruso said, though when it comes to pharmaceuticals the company is more interested in less-risky licensing agreements.

   “We’re equally interested in all three of our businesses,” Caruso said in an interview with Bloomberg News. “We’re agnostic whether it’s big or small.” That excludes a mega-merger with another drugmaker, he said.

   J&J is focused on finding value, he said, which means different things for each line of business. In the consumer unit, for example, there is relatively lower risk from a regulatory or market perspective than in other lines of business, making it potentially easier to make a purchase that can generate a worthwhile return.

   One challenge is finding assets big or differentiated enough to move the needle at the health-care products giant, which had sales of $70.1 billion last year. Its consumer, drugs and medical technology units would each be large stand-alone companies on their own.

   “It would be very hard to do something transformational for J&J,” he said. “We do look at areas where we might not be in the market today, where we might add a whole other therapeutic focus.”

   Earnings Report

   Caruso’s comments came after the company reported second-quarter earnings on Tuesday. The health care company increased its 2016 profit and sales forecasts after second-quarter profit topped analysts’ estimates, driven by growth in the pharmaceutical division. In the second quarter, earnings were $1.74 a share, excluding some items, compared with the $1.68 average of 20 predictions compiled by Bloomberg. Drug sales increased 8.9 percent during the period, helping offset a decline in consumer products, while revenue from medical devices were little changed.

   The shares were up 1.3 percent to $124.79, and are up 24 percent in the last 12 months, as of Monday’s close.

   While valuations have started to come down in the biotechnology industry, Caruso said that doesn’t mean the drugmaker is pursuing large-scale M&A in that sector.

   “Our strategy in pharma is licensing and collaborations and not major acquisitions,” he said. “That doesn’t mean we’re not going to do one.” 

   Deal Frenzy

   Caruso’s comments come during an ongoing flood of health-care transactions. In 2014 and 2015, there were $872.6 billion worth of proposed or completed deals, compared with $235.5 billion so far in 2016, according to data compiled by Bloomberg.

   In medical devices, Caruso said heart valves and cardiology devices are “some of the most exciting areas,” but that valuations aren’t at an attractive level right now. On a call with analysts, Chief Executive Officer Alex Gorsky said J&J is also interested in vision care, orthopedics and surgical deals.

   Unlike some of its competitors, J&J hasn’t done any mega-deals in the past two years. Its last large acquisition, the $19 billion purchase of Synthes Inc., was in 2012. The company also reportedly lost a bidding war for Pharmacyclics Inc. when AbbVie Inc. won with a $21 billion offer last year. J&J did its biggest acquisition in four years with the $3.3 billion agreement to purchase closely held hair-care company Vogue International, which it completed this week.

    J&J had almost $40 billion in cash, equivalents and short-term items on its balance sheet at the end of last year, according to data compiled by Bloomberg.

    

   Return to headline | Return to top

9. Johnson & Johnson tops Wall Street forecasts

   Jul 19, 2016 | USA Today

   By Kevin McCoy

   Shares of Johnson & Johnson (JNJ) rose Tuesday after the U.S. healthcare giant reported second-quarter financial results that topped Wall Street estimates and raised its full-year financial guidance for 2016.

   The results were boosted by growth in the company's pharmaceuticals division that helped offset a decline in sales of consumer health products. Investors sent Johnson & Johnson shares up 2.97% to $123.14 in trading before U.S. financial markets opened.

   The New Brunswick, N.J.-based maker of pharmaceuticals, medical devices and personal care products said sales for the three-month period rose to $18.5 billion, 3.9% higher than last year's second quarter. The result surpassed the nearly $18 billion consensus forecast of financial analysts surveyed by S&P Global Market Intelligence.

   Johnson & Johnson net earnings for the quarter fell to $3.997 billion, or $1.43 per share, down from $4.516 billion or $1.61 per share for the same period last year.

   Adjusted net earnings before provision for taxes on income came in at $6.024 billion, or $1.74 per share, a 3.6% drop from the $6.248 billion Johnson & Johnson recorded last year. Wall Street analysts had forecast adjusted earnings per share of $1.68.

   The results were announced one day after the company declared a 80-cent cash dividend for the year's third quarter and finalized its $3.3 billion acquisition of beauty products company Vogue International. The acquisition increased Johnson & Johnson's market share in the hair care products.

   The company boosted its full-year sales guidance of $71.5 billion to $72.2 billion, up from the sweetened forecast of $71.2 billion to $71.9 billion Johnson & Johnson predicted in April. The company also increased its adjusted 2016 earnings guidance to $6.63 to $6.73 per share, up from $6.53 to $6.68.

   The forecast does not include any expectation that Johnson & Johnson will face an equivalent and less expensive competitor for Remicade, the company's top-selling arthritis drug, in the near future. Chief Financial Officer Dominic Caruso told Bloomberg Go that the company would defend its patent for the medication, which he said is set to expire in 2018.

   Worldwide pharmaceutical sales rose 8.9% from the same period last year to $8.7 billion. However, global consumer sales declined 1.8% to $3.4 billion. Alex Gorsky, Johnson & Johnson's chairman and CEO, credited the increase in part to "continued success of new products" and "significant clinical milestones" in the company's drug pipeline.

   The pharmaceutical growth included rising sales of Imbruvica, a new once-daily oral therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer, the company reported.

   Johnson & Johnson also said its second-quarter results were aided by a drop in negative worldwide currency impact to 2.7% from the 6.6% in the January-March quarter.

   Return to headline | Return to top

10. Johnson & Johnson's stock surges after profit and sales beat, raised outlook

    Jul 19, 2016 | MarketWatch

    By Tomi Kilgore

    Johnson & Johnson's stock (JNJ) jumped 3.1% in premarket trade Tuesday, after the consumer and pharmaceutical products giant reported second-quarter profit and sales that beat expectations and raised its full-year outlook. For the quarter ended in June, earnings fell to $6.02 billion, or $1.43 a share, from $6.25 billion, or $1.61 a share, in the same period a year ago. Excluding non-recurring items, adjusted earnings per share came in at $1.74, above the FactSet consensus of $1.68. Revenue grew 3.9% to $18.48 billion, above the FactSet consensus of $17.98 billion, boosted by 8.9% growth in pharmaceutical sales. The company raised its 2016 EPS outlook to $6.63 to $6.73 from $6.53-$6.68 and its revenue outlook to $71.5 bln to $72.2 bln from $71.2 bln to $71.9 bln. "We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline," said Chief Executive Alex Gorsky. The stock has surged 20% year to date through Monday, while the Dow Jones Industrial Average has gained 6.4%.

    Return to headline | Return to top

11. Johnson & Johnson crushed earnings expectations and raised its guidance for the year

    Jul 19, 2016 | Business Insider

    By Akin Oyedele

    Johnson & Johnson on Tuesday reported second-quarter profits that topped estimates, and raised its guidance for the rest of the year.

    The pharmaceutical giant posted revenues of $18.5 billion, up 3.9% year-on-year, and more than analysts’ median forecast for $18 billion according to Bloomberg.

    Adjusted earnings per share came in at $1.74 ($1.68 expected.)

    “We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline,” said CEO Alex Gorsky in the earnings statement.

    The company raised its sales guidance for the full year to $72.2 billion from $71.5 billion. It boosted its EPS expectation to $6.63 – $6.73 per share.

    Global pharmaceutical sales rose 8.9% to $8.7 billion, driven by new products like Imbruvica, a lymph node cancer treatment, and Invokana, which treats type 2 diabetes.

    Johnson & Johnson shares rose as much as 3% in premarket trading.

     

    Return to headline | Return to top

12. Johnson & Johnson Lifts Full-Year Outlook as It Tops Quarterly Forecasts

    Jul 19, 2016 | MSN

    By Laura Board

    Johnson & Johnson on Tuesday posted second-quarter revenue and earnings that topped forecasts as its pharmaceuticals division continued to expand rapidly.

    The figures follow a forecast-busting first quarter, thanks also to strength in its pharmaceuticals business, and prompted the company once again to lift its full-year guidance. Johnson & Johnson shares had edged up 14 cents on Monday to $123.14. The stock has risen 27% in the past year. It was rising 3% in premarket trading on Tuesday.

    The New Brunswick, N.J.-based company said sales rose 3.9% year on year to $18.5 billion. Analysts had been expecting sales of about $18 billion. Adjusted second-quarter earnings edged up 1.8% to $1.74 a share, compared with expectations for earnings of $1.66, and $1.71 last year.

    The company said it suffered a 1.4% hit to the top line because of currency fluctuations. It also reported that it pulled in second-quarter net profit of $4.9 billion, excluding amortization and one-time items. That was a rise of 1.1%.

    "We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise," said Chairman and CEO Alex Gorsky.

    The company increased its sales guidance for the full year to between $71.5 billion and $72.2 billion, and its adjusted full-year earnings per share guidance to between $6.63 and $6.73. Back in April, it had predicted full-year sales of between $71.2 billion and $71.9 billion and earnings per share of between $6.53 and $6.68.

    Pharmaceuticals sales once again powered ahead in the second quarter, rising 8.9% to $8.7 billion.

    The company said consumer sales fell 1.8% to $3.4 billion, mainly because of currency losses, with the Neutrogena and Aveeno skincare products among its best performers.

    Medical Devices sales rose 0.8% to $6.4 billion.

    Johnson & Johnson completed several acquisitions in the quarter and last month said it would pay $3.3 billion for Vogue International, the maker of OGX shampoos. Analysts are keen to hear about its plans for the business and its strategy to revive its medical devices unit.

    Return to headline | Return to top

13. Johnson & Johnson (JNJ) Beats on Q2 Earnings, Revenues

    Jul 19, 2016 | Zacks Equity Research

    Johnson & Johnson (JNJ - Analyst Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.

    However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment. JNJ also had issues with its consumer segment manufacturing facilities. Another headwind is unfavorable currency movement.
    
    In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
    
    JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters with an average surprise of 2.13%. Estimates have also been revised upwards for 2016.
    
    Currently, JNJ has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
    
    Earnings Beat: JNJ beat on second quarter earnings - the company reported EPS of $1.74 while our consensus called for EPS of $1.67.
    
    Revenues Beat: Revenues were above expectations as well. Johnson & Johnson posted revenues of $18.5 billion, compared to our consensus estimate of $17.9 billion.
    
    Ups Guidance: J&J upped its 2016 sales guidance to $71.5 billion - $72.2 billion (guidance provided with 1Q results: $71.2 billion to $71.9 billion) and earnings guidance to $6.63 - $6.73 per share (guidance provided with 1Q results: $6.53 - $6.68 per share). The Zacks Consensus Estimate for revenues and earnings currently stands at $71.6 billion and $6.60 per share, respectively.

    Pre-Market Trading: Shares were up more than 3% in pre-market trading.

    Return to headline | Return to top

14. Stocks Movements Activity: Johnson & Johnson (NYSE:JNJ) , Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE)

    Jul 19, 2016 | Street Updates

    By Eldred Matthew

    Johnson & Johnson (NYSE:JNJ) accumulated +0.11%, closing at $123.14 after floating between $122.44 and $123.22. The company has market capitalization of $338.71B. It has twelve month low of $81.79 and twelve month high of $124.30.

    The recent traded volume of 6.6 million shares lower than its average volume of 7.15 million shares. Analyst expected twelve month price target of $120.33.

    During the most recent trading day, the stock’s price shifted up +50.56% from its 52-week low and -0.93%  lower from its 52-week high. The stock’s price moved above its 200 day moving average of $109.83. The stock is currently trading up its SMA 50 of $118.41.

    Johnson & Johnson (JNJ) recently declared that Johnson & Johnson Consumer Inc. has successfully completed the acquisition of Vogue International LLC, a privately-held company focused on the marketing, development and distribution of salon-influenced and nature inspired hair care and other personal care products, for $3.3 billion in cash.

    Johnson & Johnson’s (JNJ) EPS growth ratio for the past five years was 2.80% while Sales growth for the past five years was 2.60%. Return on equity (ROE) was noted as 21.50% while return on investment (ROI) was 16.90%. The stock’s institutional ownership stands at 66.90%.

    What Analysts Say about this Stock:

    The Company has received rating from WSJ analysts. 3 Months Ago, the stock has been rated as “Buy” from 10 Analysts. 0 analysts have suggested “Sell” for the company. 12 analysts have rated the company as a “Hold”. Overweight rating was given by 2 analysts and Underweight rating was given by 0 analysts. The stock has received “OVERWEIGHT” rating after consensus analysis from analysts.

    Ampio Pharmaceuticals, Inc. (NYSEMKT:AMPE) after beginning at $1.0500, closed at $0.9845 by cutting down -4.4175% in recent trading session. Most recent session’s volume of 1.1 million shares greater than its average volume of 853.39 thousand shares. The company has market value of $51.21M.

    Analysts have consensus one year price target of $14.0000.

    During the last trading session, the stock’s price changed -64.9552% below its 200 day moving average of $2.8093 and moving -63.6281% downbeat it’s SMA 50 of $2.7068.

    In the liquidity ratio analysis; Ampio Pharmaceuticals, Inc.’s (AMPE) debt to equity ratio was 0.00 while current ratio was 3.50. The company has the institutional ownership of 24.60% while the Beta factor was 0.14. The stock’s RSI amounts to 17.55.

    Return to headline | Return to top

15. Investors Cheer Johnson & Johnson's Q2 Results

    Jul 19, 2016 | Benzinga

    By R. Chandrasekaran

    Johnson & Johnson JNJ delivered solid results for the second quarter. The company reported 11.5 percent drop in net earnings despite sales witnessing 3.9 percent top line growth hurt by different expenses like restructuring. However, excluding adjustments, its profit would have increased 1.1 percent on YOY basis in the second quarter and came in well above the Street analysts' expectations.

    The stock traded up about 3 percent in the pre-market session.

    Johnson & Johnson reported net earnings of $4.0 billion, down from $4.52 billion while earnings per share dipped 11.2 percent to $1.43 from $1.61 in the year-ago quarter. On an adjusted basis, it would have earned $4.9 billion or $1.74 a share in the latest quarter. This was $0.06 a share higher than the Street analysts' expectations of $1.68 a share.

    Similarly, its top line grew 3.9 percent to $18.5 billion from $17.8 billion in the previous year quarter. Analysts expected the company to generate revenue of $17.97 billion. Analysts' highest revenue expectation was $18.2 billion.

    The FMCG firm said its operational sales grew 5.3% and that the currency had an unfavorable impact of 1.4 percent. Its domestic sales increased 7.4 percent while International sales advanced 0.4 percent reflecting operational growth of 3.1 percent, as well as a negative currency impact of 2.7 percent. Excluding adjustments, on an operational basis, worldwide sales would have increased 7.9 percent, domestic sales advanced 8.8 percent and international sales grew 6.9 percent.

     Johnson & Johnson said its operations in Venezuela were negatively impacted its worldwide operational sales growth by 30 basis points, and international sales uptick by 70 basis points.

     The company's chairman and CEO, Alex Gorsky, commented, "We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise. We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline."

     He added, "In our Consumer business, we are executing strategic portfolio decisions to expand our market leadership in key segments, and in Medical Devices, we are continuing to accelerate our growth driven by new product launches and transforming our commercial models... I am proud of our dedicated and talented employees whose commitment to advancing health and well-being for patients and consumers around the world is fueling our growth."

     Going forward, the company boosted its sales forecast to $71.5 billion to $72.2 billion for the full year. The Company also lifted its adjusted earnings outlook to $6.63-$6.73 per share. Both are above the Street estimations of $71.72 billion revenue and $6.61 EPS.

    Return to headline | Return to top

16. Johnson & Johnson Q2 Results Top Estimates, Lifts FY16 Forecast

    Jul 19, 2016 | RTT News

    Healthcare major Johnson & Johnson (JNJ) reported Tuesday a decline in second-quarter profit mainly hurt by higher charges. Adjusted earnings topped analysts' estimates as sales also increased above market view. Further, the company lifted its fiscal 2016 earnings and sales forecast.

    In pre-market activity on the NYSE, Johnson & Johnson shares were gaining 3.13 percent to trade at $127.

    Johnson & Johnson's net earnings for the second quarter declined 11.5 percent to $4 billion from last year's $4.52 billion. Earnings per share were $1.43, lower than $1.61 a year ago.

    Excluding certain expenses and charges, adjusted net earnings were $4.87 billion or $1.74 per share, compared to $4.81 billion or $1.71 per share a year ago.

    On average, 20 analysts polled by Thomson Reuters expected earnings of $1.68 per share for the quarter. Analysts' estimates typically exclude special items.

    Quarterly sales were $18.48 billion, an increase of 3.9 percent from last year's $17.79 billion. Analysts were looking for sales of $17.97 billion.

    Operational sales results increased 5.3 percent and the negative impact of currency was 1.4 percent.

    The company noted that worldwide operational sales growth was driven by new products and the strength of core products. The company generated higher sales in new products including cancer drug IMBRUVICA (ibrutinib), XARELTO (rivaroxaban), an oral anticoagulant, and multiple myeloma drug DARZALEX (daratumumab), among others.

     New product sales growth was negatively impacted by lower sales of OLYSIO/SOVRIAD (simeprevir) due to competitive entrants.

    In the quarter, domestic sales grew 7.4 percent, while international sales edged up 0.4 percent, reflecting operational growth of 3.1 percent and a negative currency impact of 2.7 percent.

    Excluding the net impact of acquisitions, divestitures and hepatitis C sales, on an operational basis, worldwide sales increased 7.9 percent, domestic sales increased 8.8 percent and international sales increased 6.9 percent.

    The company noted that operations in Venezuela negatively impacted worldwide operational sales growth by 30 basis points, and international sales growth by 70 basis points.

    Worldwide Consumer sales decreased 1.8 percent, mainly due to weak international sales. Pharmaceutical sales, however, grew 8.9 percent, and Medical Devices sales edged up 0.8 percent.

    Alex Gorsky, Chairman and Chief Executive Officer, said, "We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise. We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline."

    Looking ahead, for fiscal 2016, the company now expects adjusted earnings of $6.63 to $6.73 per share, and sales of $71.5 billion to $72.2 billion.

    The company previously expected full-year adjusted earnings in a range of $6.53 - $6.68 per share and sales of $71.2 billion to $71.9 billion

    Wall Street expect annual earnings of $6.61 per share and revenues of $71.72 billion.

    Return to headline | Return to top

17. Johnson & Johnson (JNJ) Posts Earnings Results, Beats Expectations By $0.05 EPS

    Jul 19, 2016 | Sleek Money

    By Jamal Genner

    Johnson & Johnson (NYSE:JNJ) posted its earnings results on Tuesday. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.05. The business had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion.

     In other news, CAO Ronald A. Kapusta sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, June 7th. The shares were sold at an average price of $115.79, for a total transaction of $347,370.00. Following the transaction, the chief accounting officer now directly owns 28,725 shares in the company, valued at $3,326,067.75. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Ronald A. Kapusta sold 3,957 shares of the firm’s stock in a transaction that occurred on Tuesday, May 10th. The stock was sold at an average price of $114.77, for a total transaction of $454,144.89. Following the transaction, the chief accounting officer now owns 29,682 shares in the company, valued at $3,406,603.14. The disclosure for this sale can be found here.

     Shares of Johnson & Johnson (NYSE:JNJ) opened at 123.14 on Tuesday. The company has a 50-day moving average of $118.41 and a 200 day moving average of $109.83. The stock has a market cap of $338.71 billion and a price-to-earnings ratio of 22.44. Johnson & Johnson has a one year low of $81.79 and a one year high of $124.30.

     The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 2.60%. The ex-dividend date of this dividend is Friday, August 19th.

     A number of research analysts have recently issued reports on the stock. JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, April 17th. BTIG Research reaffirmed a “hold” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Leerink Swann reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Sunday, May 22nd. Finally, Deutsche Bank AG reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, April 6th. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company. Johnson & Johnson presently has a consensus rating of “Hold” and an average target price of $112.77.

     Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

18. J&J hikes forecast as standouts Imbruvica, Xarelto crank up pharma growth

    Jul 19, 2016 | Fierce Pharma

    By Tracy Staton

    Once again, Johnson & Johnson’s pharma engine powered top-line growth, with top performers Imbruvica, Xarelto and Daklinza all racking up impressive gains. Thanks to that “notable strength,” the healthcare giant hiked its sales and earnings forecasts for the year.
    
    J&J’s pharmaceuticals sales vaulted ahead by almost 9% to $8.7 billion--even after currency effects--which helped jack up overall sales by 3.9%. Meanwhile, consumer sales slipped (down 1.8%) and devices squeaked out a tiny increase (0.8%).
    
    Standout meds? Imbruvica, the blood cancer drug, which racked up global gains and now leads the market in second-line leukemia treatment, J&J said in a Tuesday investor presentation. The drug, shared with AbbVie, brought in $295 million for the quarter, more than half of that overseas.
    
    Then there’s Xarelto, a reliable growth driver, with $594 million in sales, up more than 25%. J&J likes to brag about its market share among oral anticoagulants: Now 16.9% of the overall market, despite blockbuster rivals from Bristol-Myers Squibb and Pfizer, and Boehringer Ingelheim.
    
    Some other big percentage increases--on the prostate cancer med Zytiga and anti-inflammatory Stelara, for instance--were fueled partly by adjustments to the funds J&J had set aside to cover gross-to-net charges. Apparently, the drugs haven’t been hit as hard as expected by discounts and rebates, which surface only after initial sales are booked.
    
    Zytiga’s sales line amounted to $601 million worldwide, and Stelara’s stood at $804 million, a global hike of 41.1%.
    
    J&J will need all the help it can get from these fast-growing products, what with biosimilar competition to its top seller, Remicade, coming down the pike. Pfizer and partner Celltrion say they’re raring to go with their biosim version, but as of last quarter’s earnings call, J&J CFO Dominic Caruso was insisting that Remicade won’t face copycats in the U.S. this year.
    
    Meanwhile, on the flip side of J&J’s pharma growth, the company’s hepatitis C drugs continued to drag down overall pharma growth. To be expected, now that Olysio faces formidable competition from Gilead Sciences’ Sovaldi and Harvoni, AbbVie’s Viekira Pak, and Merck & Co’s new entrant Zepatier, which carries a much lower list price than its predecessors. Gilead’s latest approval for an all-genotype hep C fighter, Epclusa, poses yet another threat.
    
    On the consumer side, J&J saw increases in its over-the-counter meds, which accounted for $1 billion in sales. Pain relievers such as Tylenol pitched in the most--worldwide growth amounted to 13%--while allergy meds, including Zyrtec, faltered on seasonal weakness. J&J’s oral care line also grew strongly, mostly in thanks to its Listerine brand, which has added some new products and launched marketing campaigns.
    
    CEO Alex Gorsky touted J&J’s “good momentum” for the first half of the year, citing “notable strength in our pharmaceuticals business” thanks to “continued success of new products.” And Gorsky pointed out that more new meds are on the horizon: Pharma R&D “achieved significant clinical milestones” in the quarter, he said.

    Return to headline | Return to top

19. Shares of Johnson & Johnson (JNJ) Sees Large Inflow of Net Money Flow

    Jul 19, 2016 | Founders Daily

    By Don Renner

    Johnson & Johnson (JNJ) : Johnson & Johnson (JNJ) had a healthy money flow of $1.61 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $51.43 million, whereas, investors only sold shares worth $49.82 million on downticks. The stock closed the day with an up-down ratio of 1.03.The money flow in the block trades to the tune of $0.25 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $5.52 million worth of transactions were on upticks. A paltry $5.27 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 1.05. Johnson & Johnson (JNJ) stock slid $0.19 intraday and traded at 122.81, a change of -0.15% over previous days close. However, for the week, the company shares are -0.03% compared to previous weeks close.

    Johnson & Johnson is up 11.8% in the last 3-month period. Year-to-Date the stock performance stands at 21.61%. Shares of Johnson & Johnson rose by 0.17% in the last five trading days and 5.57% for the last 4 weeks. In a related news, The officer (Exec VP, WW Chair, Med Devices), of Johnson & Johnson, Pruden Gary J had unloaded 9,735 shares at $116.03 per share in a transaction on June 7, 2016. The total value of transaction was $1,129,552. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

    Johnson & Johnson (NYSE:JNJ): stock turned positive on Monday. Though the stock opened at $123, the bulls momentum made the stock top out at $123.22 level for the day. The stock recorded a low of $122.44 and closed the trading day at $123.14, in the green by 0.11%. The total traded volume for the day was 6,599,199. The stock had closed at $123 in the previous days trading.

    Johnson & Johnson is a holding company. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

    Return to headline | Return to top

20. Johnson & Johnson (JNJ) to Issue $0.80 Quarterly Dividend

    Jul 19, 2016 | Ambiente Ja

    By Adalberto Braga

    The company most recent volume stood at 7.19 million shares as compared to average volume of 7.16 million shares. The stock revealed the change of -0.15% with down momentum. The stock ended last trading session with the price almost 0.12 higher for the last 5 trading days, rebounding 53.68% from its 52-week low. Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to "Sell", Price Target of the shares are set at $94.Company shares were Reiterated by RBC Capital Mkts on April 20, 2016 to "Outperform", Firm has raised the Price Target to $ 125 from a previous price target of $122.Company shares were Reiterated by Piper Jaffray on April 20, 2016 to "Neutral", Firm has raised the Price Target to $ 106 from a previous price target of $105.

    The company has a P/E ratio of 22.42. They issued a "hold" rating and a $113.00 price objective for the company. If we take a look on its volatility, 0.84 percent was seen in a week and for the month it was 1.07 percent. The corporation holds 2754.67 million outstanding shares and its 2749.85 million shares were floated in the market.

    FactSet analysts have an average overweight rating on the stock with a price target of $118.68, which is below its current level of about $123. Underperform rating was given by 0 analyst and Outperform rating was given by 5 analyst. Current revenue movements show that, the company has set average revenue estimates of 17.98B covering forecast of 16 analysts.

    Per the company's financial guidance for 2016, revenues are estimated to come in between $71.9 billion and $72.6 billion, which is almost 2.5%-3.5% higher than 2015 revenues of $70.0 billion. The remarkable sales forecast has been decided at $76.15B while reduced sales figure was expected at $74.05B. Piper Jaffray Cos. reissued an "overweight" rating and issued a $105.00 target price on shares of Johnson & Johnson in a report on Sunday, March 20th. The stock traded down to $122.71 during the day, due to lack of any buying support eventually closed down at $123.00 with a loss of -0.15% for the day. 0 analysts have suggested "Sell" for the company. Earlier this year, the company said  it would ut about 3,000 jobs at the division and make cuts aimed at saving $800 million to $1.0 billion by the end of 2018.

    Return to headline | Return to top

21. J&J quarterly sales rise 3.9 percent

    Jul 19, 2016 | Pop Herald

    By Vicki Perkins

    It has 1.86B of outstanding shares and its shares float measured at 1.19B.

    Johnson & Johnson (NYSE:JNJ): The stock opened at $123.77 on Friday but the bulls could not build on the opening and the stock topped out at $124.30 for the day.

    The company Insiders own 0.11% of Johnson & Johnson shares according to the proxy statements. Johnson & Johnson makes up approx 8.52% of Boulegeris Investments's portfolio. Lgt Capital Partners Ltd. reduced its stake in JNJ by selling 49,000 shares or 48.61% in the most recent quarter. The Hedge Fund company now holds 209,859 shares of JNJ which is valued at $25,812,657. For the quarter ended in June, earnings fell to $6.02 billion, or $1.43 a share, from $6.25 billion, or $1.61 a share, in the same period a year ago.

    Shares of Johnson & Johnson (NYSE:JNJ) traded up 0.11% during midday trading on Monday, reaching $123.14.

    Diversified health care company Johnson & Johnson reported a 3.9 per cent increase in second-quarter sales, helped by strength in its pharmaceuticals business. Revenue came in at 17.48B versus consensus estimate of 17.48B.

    The drugmaker holds a strong track record in surpassing analysts' expectations and might be expected to exhibit the same in the latest quarter too. The analysts' current consensus range is $1.63-$1.71 for EPS.

    The pharmaceutical segment of the firm will continue to be the top revenue generating area for the latest quarter with contribution of more than 46% toward total sales of the company. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have issued a buy rating to the company. Johnson & Johnson is set to release its 2Q16 earnings on July 19, 2016. The Company is engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has been boosting its dividend for more than five decades. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Companys subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Company's research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom. 

    Return to headline | Return to top

22. Boulegeris Investments buys $12883389 stake in Johnson & Johnson (JNJ)

    Jul 19, 2016 | Nano News

    By Jack Bowen

    The company indicated that the stock would turn into ex-dividend on August 19.

    “Consensus does not fully recognize the value of the pipeline – we think the Street fails to capture much of the potential upside from the company’s pharmaceutical pipeline and line extensions”, analysts said in a note. Based on the most relevant historical data, there is a 53.85 percent probability for share price to go down following the next earnings report.

    Johnson & Johnson’s stock has returned almost 27% over the last 12 months, while that of its competitor Pfizer (PFE) has risen by 7.4%. Institutional Investors own 68.05% of Johnson & Johnson shares.

    So how did JNJ’s earnings announcements affect its stock price in the past few quarters? Current revenue movements show that, the company has set average revenue estimates of 17.98B covering forecast of 16 analysts. The stock has recorded a 20-day Moving Average of 2.79% and the 50-Day Moving Average is 5.85%.

    Per the company’s financial guidance for 2016, revenues are estimated to come in between $71.9 billion and $72.6 billion, which is almost 2.5%-3.5% higher than 2015 revenues of $70.0 billion. The stock gained 4.96% the day following the earnings was released, and on 7th day price change was 8.26%. The company posted a positive surprise factor of 1.18% by 0.02. The stock experienced a loss of -0.11% and settled its last trade at $123.00. The company’s net adjusted income is expected to increase by ~2% to ~$4.7 billion in 2Q16 as compared to 2Q15. The remarkable sales forecast has been decided at $76.15B while reduced sales figure was expected at $74.05B. Now shares have been rated as “Buy” from 5 Analysts. The stock floated in a price range of $122.71 to $124.30, with market capitalization of $337.83M.

    Johnson & Johnson (NYSE:JNJ) last closed at $123, sending the company’s market cap around $338.33B. The share price has declined -0.6% from its best level in 52 weeks and dropped 21.47% this year.

    Return to headline | Return to top

23. Jefferies Group Boosts Johnson & Johnson (JNJ) Price Target to $113.00

    Jul 19, 2016 | WKRB News & Analysis

    By Scott Davis

    Johnson & Johnson (NYSE:JNJ) had its price objective raised by Jefferies Group from $109.00 to $113.00 in a report issued on Thursday morning. The firm currently has a hold rating on the stock.

    Other research analysts also recently issued research reports about the company. JPMorgan Chase & Co. reiterated a hold rating on shares of Johnson & Johnson in a report on Sunday, April 17th. Royal Bank Of Canada reiterated a buy rating on shares of Johnson & Johnson in a report on Sunday, April 17th. BTIG Research reiterated a hold rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Leerink Swann reiterated a buy rating on shares of Johnson & Johnson in a report on Sunday, May 22nd. Finally, Piper Jaffray Cos. upped their target price on Johnson & Johnson from $105.00 to $106.00 and gave the stock a neutral rating in a report on Wednesday, April 20th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus price target of $112.77.

    In related news, VP Gary J. Pruden sold 9,735 shares of the firm’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $116.03, for a total value of $1,129,552.05. Following the transaction, the vice president now directly owns 43,630 shares of the company’s stock, valued at approximately $5,062,388.90. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CAO Ronald A. Kapusta sold 3,957 shares of the firm’s stock in a transaction on Tuesday, May 10th. The stock was sold at an average price of $114.77, for a total value of $454,144.89. Following the completion of the transaction, the chief accounting officer now directly owns 29,682 shares in the company, valued at $3,406,603.14. The disclosure for this sale can be found here.

    Other institutional investors recently made changes to their positions in the company. Americafirst Capital Management LLC bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $101,000. Stelac Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $192,000. Capital Asset Advisory Services LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $202,000. Magnetar Financial LLC acquired a new stake in shares of Johnson & Johnson during the first quarter worth about $223,000. Finally, D. Scott Neal Inc. raised its stake in shares of Johnson & Johnson by 4.1% in the second quarter. D. Scott Neal Inc. now owns 1,840 shares of the company’s stock worth $223,000 after buying an additional 72 shares during the last quarter.

    Shares of Johnson & Johnson (NYSE:JNJ) traded up 1.74% on Thursday, reaching $125.28. The company’s stock had a trading volume of 6,786,346 shares. Johnson & Johnson has a 12-month low of $81.79 and a 12-month high of $125.75. The company has a market cap of $344.60 billion and a P/E ratio of 22.83. The company’s 50 day moving average price is $118.41 and its 200 day moving average price is $109.83.

    Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating analysts’ consensus estimates of $1.69 by $0.05. The business had revenue of $18.50 billion for the quarter, compared to the consensus estimate of $17.98 billion. Analysts forecast that Johnson & Johnson will post $6.61 EPS for the current fiscal year.

    The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be issued a $0.80 dividend. The ex-dividend date of this dividend is Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a yield of 2.60%.

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

    Return to headline | Return to top

24. Johnson & Johnson Q2 Earnings, Guidance Beat (JNJ)

    Jul 19, 2016 | MSN

    By Richard Saintvilus

    Shares of Johnson & Johnson Corporation (JNJ) are rising about 1.5% higher in the Monday's early trading session after the global healthcare conglomerate reported second quarter fiscal 2016 earnings results that beat Wall Street's estimates. Combined with its upbeat outlook, the company's confidence not only implies market share gains it its pharmaceutical segment, but also affirms that its 20% year-to-date stock gains have been no fluke. (See also: Behind Johnson & Johnson's 91.5% Rise in 10 Years.)

    For the three months that ended June, the New Jersey-based firm reported an adjusted profit of $1.74 in earnings per share on $18.5 billion in revenue, compared to the year-ago quarter when it earned $1.71 per share on revenue of $17.79 billion. The results surpass Wall Street's estimates of $1.68 per share on revenue of $17.97 billion. 

    As been the case for the past several quarters, the company's dominant drug business was the main driver of growth. Johnson & Johnson's Pharmaceutical revenue grew 9% year over year to $8.65 billion, accounting for about 47% of total revenue. This more than offset a 1.8% decline in the Consumer segment, which produced $3.4 billion in revenue, while the Medical Devices & Diagnostics segment grew about 0.8% to $6.4 billion.

    "We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline," said CEO Alex Gorsky in a statement. "In our Consumer business, we are executing strategic portfolio decisions to expand our market leadership in key segments, and in Medical Devices, we are continuing to accelerate our growth driven by new product launches and transforming our commercial models."

    On a geographical basis, U.S. revenue grew 7.4% year over year to $9.5 billion. Johnson & Johnson suffered 3.3% negative impact from currency, which lead to a 1.5% decline in Europe sales, reaching $4.09 billion. This was partially offset by 1.7% rise Asia Pacific & Africa and 2.7% increase in W. Hemisphere (ex-U.S.).

    Looking ahead toward fiscal 2016, Johnson & Johnson expects to have EPS in the range of $6.63 to $6.73 and revenue  in the range of $71.5 billion to $72.2 billion.

    This compares to consensus estimates are $6.61 in earnings per share, while revenue is projected to be $71.72 billion.

    Johnson & Johnson shares have risen about 25% over the past year, while S&P 500 index has risen 1.6%. 

    Return to headline | Return to top

25. Johnson & Johnson: JNJ Stock Looks Even Better After Earnings

    Jul 19, 2016 | Investor Place

    By Dan Burrows

    Johnson & Johnson (NYSE:JNJ) delivered Wall Street’s favorite earnings treat — a beat and raise quarter — setting JNJ stock up to build handsomely on what has already been an enviable year of gains.

    The diversified healthcare company’s pharmaceutical segment was the standout driving top-line growth. Thanks to JNJ’s Imbruvica cancer drug, Xarelto blood thinner and Remade — an arthritis drug and J&J’s biggest seller — JNJ pharma sales rose almost 9% to $8.7 billion. Remicade sales rose 6.7% to $1.78 billion alone.

    CEO Alex Gorsky said in a statement:

    “We saw notable strength in our Pharmaceuticals business due to the continued success of new products, and also achieved significant clinical milestones, advancing our robust pipeline.”

    Results from other business segments were mixed. Johnson & Johnson consumer health products sales fell almost 2% to $3.4 billion as Venezuela devalued its currency. However, sales of medical devices increased nearly 1% to $6.4 billion, which accounted for more than two-thirds of the top line.

    Taken together, JNJ’s sales rose 3.9% to $18.5 billion, easily topping analysts’ average estimate of $17.98 billion, according to a survey by Thomson Reuters.

    JNJ Stock Easy to Love on Guidance Hike

    The better-than-expected top-line results helped JNJ exceed the Street’s average earnings forecast by a wide margin. On a net basis, profit fell to $4 billion, or $1.43 a share of JNJ stock, from $4.52 billion, or $1.61 a share, in last year’s quarter. But on an adjusted basis — which is what analysts and investors care about — earnings came to $1.74, while the Street was looking for earnings of $1.68 a share.

    Of course, the most important news for the future trajectory of JNJ stock is guidance, which the company lifted significantly. For the full fiscal year, Johnson & Johnson now sees adjusted earnings coming in at anywhere $6.63 to $6.73 a share. Analysts’ average estimate stands at $6.61, so we can expect that to come up.

    Revenue is now targeted at $71.5 billion to $72.2 billion, versus the current Street estimate of $71.72 billion.

    With JNJ stock up 20% for the year-to-date ahead of the encouraging earnings report, it’s natural to expect even more outperformance in the months ahead.

    Return to headline | Return to top

26. Johnson & Johnson's Unstylish Sprawl Looks Good

    Jul 19, 2016 | Bloomberg Gadfly

    By Max Nisen

    Conglomerates are out of style -- particularly in health care, which has seen a decade of spinoffs, sales, and asset swaps aimed at greater focus. Johnson & Johnson has bucked that trend, even as some of its units have struggled. But sometimes being out of step is the right move. 

    The company on Tuesday reported second-quarter earnings that topped Wall Street forecasts and boosted revenue guidance for the year, thanks to its pharmaceutical division, which grew sales 8.9 percent from a year ago. In contrast, the company's consumer-products sales declined 1.8 percent, and sales of medical devices grew just 0.8 percent. Those businesses have been laggards for a while, and investors have called for J&J to break up or sell those units.

    But J&J's unfashionable sprawl has made a relatively safe haven in a turbulent and anxious market, particularly for pharma stocks. Its shares rose more than 1 percent on Tuesday to new highs.

    &J is managing to have it multiple ways right now. The company is seen as uniquely safe due to its size and the diversity of its business, despite the fact that nearly half of its sales come from potentially risky markets outside the U.S. And it is delivering all of the growth and potential an investor could want via its pharma division. It has $39 billion in cash and marketable securities on hand for M&A, and room to be patient in deploying it. That helps it appeal both to investors looking for upside, and those terrified of downside. 

    If nascent turnarounds in its device and consumer businesses take hold, then the company will look even more appealing. Pharma, which accounts for 46.8 percent of sales, has been J&J's rock star for the past year, with nearly all of its biggest drugs beating expectations. The other businesses are flattish or declining. The device business was once the company's biggest, at 40 percent of sales as recently as 2013. It's now down to 34.7 percent. Consumer sales produced 18.5 percent of total revenue in the second quarter, down from 25.5 percent back in 2009. 

    J&J has been restructuring the device unit, and the consumer unit is still dealing with the aftermath of a series of recalls and quality control scandals. But both businesses seem to have stabilized. Excluding acquisitions and divestitures, operational sales in devices grew 3.9 percent year-over-year in the quarter. Excluding negative currency impact, consumer sales grew 1.5 percent year-over-year, and the division's margins are improving.

    Return to headline | Return to top

27. Johnson & Johnson Keeps Growing on Pharma Strength

    Jul 19, 2016 | The Motley Fool

    Healthcare giant Johnson & Johnson (NYSE:JNJ) has been a household name for decades, with mainstays like Band-Aid and Tylenol helping to drive consumer awareness of the company's extensive product list. Yet the consumer segment is now Johnson & Johnson's smallest in terms of sales, and the conglomerate's efforts to expand in the pharmaceutical and medical device arena have been vital to the company's overall success. Coming into Tuesday's second-quarter financial report, J&J investors were somewhat concerned that the company wouldn't be able to keep its bottom line moving upward. However, its results quashed those concerns and showed signs of life in some of the most challenging areas for J&J recently.

    Let's look more closely at how Johnson & Johnson did and what the future looks like for the healthcare giant.

    J&J keeps looking stronger

    Johnson & Johnson's second-quarter financials indicated that growth appears to be accelerating for the company. Revenue rose nearly 4% to $18.48 billion, and that was more than half a billion dollars higher than most investors following the stock had expected. One-time items pulled GAAP earnings downward, but after accounting for those extraordinary items, adjusted earnings of $1.74 per share were up from the year-ago quarter and topped the consensus forecast among investors by $0.06 per share.

    One contributing factor to the improvement in Johnson & Johnson's results is that the U.S. dollar's strength has started to wane. Adverse currency effects still cost J&J some of its revenue, but the downward hit was only 1.4 percentage points, which was less than half of the impact from the first quarter of 2016. The conglomerate's international business suffered 2.7 percentage points of downward pressure on revenue, concentrated largely on the consumer business and on the Western Hemisphere, excluding the U.S., but the general trend pointed toward less of a drag on J&J's business coming from the dollar going forward.

    Strength in J&J's pharmaceutical division once again overwhelmed what its other segments were able to produce. Pharma sales jumped almost 9% during the quarter, while the medical device unit only managed a tepid 0.8% increase. Consumer sales actually fell 1.8% for the quarter, although the division's domestic operations rebounded by reversing first-quarter declines with a solid gain of more than 2%.

    From a geographical standpoint, the U.S. business carried the weight for Johnson & Johnson, with international revenue just barely rising in dollar terms. Europe was the weakest in terms of top-line performance, while the Western Hemisphere outside the U.S. managed to overcome double-digit percentage currency pressures to produce the best overall gains.

    Details on Johnson & Johnson's biggest growth drivers showed some minor changes but were generally consistent with past quarters. Skin-care and oral-care products were strong for the consumer segment, while the company pointed to psoriasis and arthritis fighter Stelara and anti-inflammatories Simponi and Remicade as key treatments in producing pharma-division growth. Rising demand for joint reconstruction products, endocutters, and Acuvue contact lenses helped keep the medical device segment solid.

    What's next for Johnson & Johnson?

    CEO Alex Gorsky was pleased with the results. "We continue to see good momentum through the first half of 2016," Gorsky said, and he noted that pharma gains came from "the continued success of new products" and the achievement of "significant clinical milestones advancing our robust pipeline." A focus on building market leadership in key consumer segments while launching new medical-device lines should promote future growth.

    As a result, Johnson & Johnson increased its guidance for the year. The healthcare giant increased its revenue projections by $300 million to a range of $71.5 billion to $72.2 billion. An increase of between a nickel and a dime per share produced new adjusted earnings guidance of $6.63 to $6.73 per share.

    Looking ahead, J&J hopes some key approvals will produce greater sales. The company's Invokamet treatment for type 2 diabetes received an additional indication from the U.S. Food and Drug Administration, and an expanded label for Imbruvica to include survival and combination data for leukemia and lymphoma patients could lead more physicians to prescribe the drugs. Similar moves from the European Commission with respect to myeloma treatment Darzalex, schizophrenia drug Trevicta, and arthritis drug Simponi, along with Imbruvica, could also help international results.

    Investors celebrated Johnson & Johnson's results, sending the stock up more than 2% in pre-market trading after the announcement. Given how well the company has been able to ride the success of its pharmaceutical unit, Johnson & Johnson will have even greater potential for gains if it can succeed in its efforts to squeeze more from medical devices and consumer products going forward.

    Return to headline | Return to top

28. Jim Cramer — J&J Is an Absolutely Terrific Stock

    Jul 19, 2016 | The Street

    By Bret Kenwell

    Shares of Johnson & Johnson (JNJ) are up 1.6% Tuesday after the drug and consumer products company topped earnings per share and revenue expectations.

    A sub-2% gain may not seem impressive but for a stock that's already rallied some 25% over the past year, how much more can be expected? This quarter justifies that big rally, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said on CNBC's "Mad Dash" segment.

    "It has small-cap growth for one of the largest, greatest companies on earth," Cramer said, explaining that J&J is a premium, large-cap growth stock.

    "Drug after drug after drug" continues to do well, he added, pointing out notable successes such as Imbruvica, Darzalex and Xarelto. CEO Alex Gorsky has been able to deliver time and time again on the high-growth pharmaceutical business. The Tylenol and orthopedic businesses also improved, Cramer said.

    Even other great large-cap companies such as Bristol-Myers Squibb (BMY)  can't keep pace with Johnson and Johnson, he said.

    So can the stock sustain its run? Once the dust settles this is an "absolutely terrific stock to own," Cramer concluded.

    Return to headline | Return to top

29. Johnson & Johnson (JNJ) CFO Caruso Is 'Very Happy With Results' He Tells CNBC

    Jul 19, 2016 | The Street

    By Giovanni Bruno

    NEW YORK (TheStreet) --Johnson & Johnson (JNJ) reported its second quarter earnings Tuesday morning and the results were better than anticipated. The company's adjusted earnings per share exceeded expectations coming in at $1.74, above the the forecast of $1.68. 

    The company posted revenue of $18.5 billion, up 3.9% year-on-year, also better than what most analysts predicted, which was around $18 billion, according to Bloomberg. 

    Johnson & Johnson CFO Dominic Caruso joined CNBC's "Squawk Box" this morning to discuss the report and the company's mission moving forward.

    Caruso, first was asked to relay clarity on what exactly Johnson & Johnson is in the business of, be it healthcare, pharmaceuticals, medical devices or consumer products.

    "We're all three of those things and our businesses are performing well. Overall we're broadly based in human health care and we think that's the right way to approach an ever-evolving health care environment," Caruso explained, saying that second quarter results are strong across all three businesses.

    Caruso plans to accelerate the company's growth by "Continuing momentum in pharmaceuticals, gaining share and consumer, making good choices to enter areas to expand market leadership (the acquisition of Vogue), and our medical device businesses is improving."

    Johnson & Johnson raised its earnings per share and sales guidance for the year due to growth in profitability and the company's second quarter success.

    Speaking to the success of the pharmaceutical sector of the business and the company's most successful prescription drug, Caruso relayed continued innovation and expansion.

    "A big part of our business is a strong pharmaceutical business where we continue to launch new products, build robust pipelines, and we're proud of the growth. They are progressing well across the market, gaining share, and improving profitability," Caruso noted.

    Return to headline | Return to top

30. J&J reports high sales growth despite increased litigation cost

    Jul 19, 2016 | BioPharma

    By Edwin Lopez

    Dive Brief:

    Johnson & Johnson's pharmaceutical worldwide sales increased by 8.9% in the second quarter compared to a year prior, with $8.7 billion in overall sales. U.S. pharmaceutical revenue jumped higher, growing by 13.2%, while international sales growth was more muted. 

    Four drugs drove growth for the drugs unit: altogether Imbruvica, Xarelto, Stilara and Simponi pulled in $637 million in new revenue, representing 90% of overall sales growth. Notably, sales of Stilara hit $570 million, while Imbruvica recorded a 91.6% in worldwide growth as Q2 sales nearly doubled to $295 million. 

    But Johnson & Johnson's litigation costs also skyrocketed last quarter, totaling $600 million prior to tax adjustments—a 326% increase from the $141 million spent prior to tax adjustments for litigation in 2015. 

    Dive Insight:

    "We continue to see good momentum through the first half of 2016, delivering solid results in the second quarter, supported by strong underlying growth across our enterprise," said Alex Gorsky, Chairman and Chief Executive Officer.

    The company has many reasons to be optimistic: U.S. sales grew by a marked amount last quarter; the pharmaceutical subsidiary secured approval of Darcylex, Trevicta and an additional Imbruvica indication in the EU; the FDA granted yet another breakthrough indication to Imbruvica; and pipeline clinical trials are advancing with few setbacks, according to the conference call this morning. 

    But buried in the details J&J reported increases litigation expenses as the company faces numerous lawsuits over Risperdal-induced gynecomastia and a potential link from their talcum powder to ovarian cancer. 

    According to financial statements, the company spent $600 million in litigation costs last quarter before tax considerations. This is sharply higher than the $66 million in expense reported last quarter and over four times the total from last year.

    Of course, the reported expenses are shared across all J&J subsidiaries and this quarter's uptick in litigation expenses may just be a return to the norm. In 2014, the company reportedly paid $1.1 billion in litigation before provisions for taxes on income, and in 2013 litigation costs surpassed $2 billion according to the company's annual reports.

    Return to headline | Return to top

31. Johnson & Johnson (JNJ) Stock Rises, CFO Talks M&A

    Jul 19, 2016 | The Street

    By Annie Palmer

    NEW YORK (TheStreet) -- Shares of Johnson & Johnson  (JNJ)  are climbing 1.75% to $125.27 in afternoon trading today as the New Brunswick, NJ-based medical and pharmaceutical manufacturer's CFO Dominic Caruso says the company is considering mergers, Bloomberg reports. 

    Earlier today, J&J posted better-than-expected 2016 second quarter earnings before the market open.

    Caruso noted that he's "agnostic" about the size of any possible deals, but that he'd prefer licensing agreements relative to the pharmaceutical division, according to Bloomberg.

    Johnson & Johnson is now looking at ways to help fill gaps the company has in the market, such as by creating a new "therapeutic focus," Caruso said. 

    For the quarter, Johnson & Johnson reported adjusted earnings of $1.74 per share on revenue of $18.5 billion. Analysts expected earnings of $1.67 per share on revenue of $17.9 billion. 

    Earnings were up 1.8% from 2015, while revenue grew 3.9% year over year. 

    Still, baby care sales slumped to $104 million in the second quarter compared to $106 million in the 2015 second quarter.

    Separately, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author. TheStreet Ratings has this to say about the recommendation:

    We rate JOHNSON & JOHNSON as a Buy with a ratings score of A. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow.

    Return to headline | Return to top

32. Drug Group Lifts J&J; Shares Still Overvalued

    Jul 19, 2016 | Morningstar

    By Damien Conover

    Driven largely by outperformance in its drug group,   Johnson & Johnson (JNJ)reported second-quarter results exceeding both our and consensus expectations, and we plan to slightly raise our fair value estimate. Nevertheless, we continue to view the stock as slightly overvalued, with increasing concerns for generic or biosimilar competition for complex drugs Concerta, Invega Sustenna, Risperdal Consta, and Remicade, which collectively represent over $10 billion in annual sales. Despite these concerns, we remain confident in the company’s wide moat, driven by steady innovation in the drug and device group coupled with solid brand power in the consumer group.

    While partly supported by reserve adjustments in the quarter, the drug group continues to lead the company, with 13% normalized growth supported by both mature and new drugs. However, we expect this growth to decelerate in 2017 as branded competition increases and generics launch on complex older drugs. On the branded side, new competing immunology drugs (Novartis’ Cosentyx, Eli Lilly’s Taltz, and Takeda’s Entyvio) are likely to take market share from Johnson & Johnson's largest drug segment of immunology drugs. Further, we expect biosimilar Remicade to cause close to 20% annual declines in J&J’s branded Remicade sales by 2018.

    While older drugs face increased competition, new drugs are mitigating the pressures. In particular, recently launched cancer drugs Imbruvica and Darzalex are posting rapid growth supported by excellent clinical data. Further, we expect immunology drug guselkumab will help J&J maintain its leadership in immunology based on the drug’s superior efficacy profile to AbbVie’s Humira in psoriasis.

    Further helping support the bottom line, cost-reduction programs in consumer and device divisions should lead to almost 500 basis points of margin expansion for the company. As the consumer group finally fixes its manufacturing issues, we expect strong leverage from this segment.

    Return to headline | Return to top

33. J&J Climbs on 2Q Earnings Beat

    Jul 19, 2016 | The Street

    By Alicia McElhaney

    Johnson & Johnson (JNJ)  share prices reached new heights Tuesday morning after reporting better-than-expected second quarter earnings.

    Shares in the pharmaceutical company, which has a market cap of $343.7 billion, hit $127, an all time high, in pre-opening trading Tuesday, after its reported earnings per share of $1.74 beat Wall Street's consensus estimate by six cents. The stock fell back to $124.54 by mid-morning, though it was still up approximately 1% from the market's open.

    "They have such great organic growth," said Jim Cramer, founder of TheStreet. "They have an anti-cancer franchise that's really re-rating them. That's how the stock is going."

    He noted that the company hasn't had to do what most other large cap pharmaceutical players have—acquire a biotech company—to keep up that growth.

    "This is the fastest growing pharmaceutical company other than Bristol Myers in pure drugs," Cramer said. "They just keep coming up with big drug after big drug."

    Sales for the second quarter were up 2.3%, from to $36 million from $35.2 billion from the same period in 2015. Sales in the U.S. rose at more than three times that clip, at 7.4%.

    Not all segments saw growth, however. Baby care, for one, saw yet another slump in sales, to $102 million in the second quarter of 2016 from $104 million for last year's second quarter.

    Alex Gorsky, CEO of Johnson and Johnson, conceded as much during Tuesday morning's earnings call, noting that the company needs to improve in its baby care segments and make further inroads in China.

    Gorsky and the other J&J executives on the call said they would stick to their current M&A strategy.

    "The M&A approach that we talked about in the past is a balanced one," Gorsky said, noting that the most of the 124 deals J&J has done in the past 14 years have been smallish.

    "We look at tuck-ins, midsize and large deals," he said. "Tuck-ins are those where we feel we can make the most value."

    In the second quarter, J&J completed five, including NeuWave Medical, BioMedical Enterprises, HIPOGLOS, NeoStrata and Vogue International.

    Gorsky added that within the medical device division, the company can look to grow, particularly in vision, including devices within eyes or surgical devices.

    However, high purchase prices could hold back further acquisitions in the near term. 

    "There are some expectations that are still not normalized for appropriate valuations in the market," Dominic Caruso, chief financial officer of JNJ said during the earnings call. "That's a factor that'll take time and we're patient with that."

    Caruso also dismissed investor concerns that M&A is hamstrung because J&J holds much of its cash overseas to avoid U.S. tax.

    "Whether or not the cash is trapped overseas or not is not at all an impediment in our ability to do acquisitions," he said." We'll obviously try to find a way to do [deals] on a tax efficient basis, but we can continue to borrow to do the acquisitions."

    Return to headline | Return to top

34. Johnson & Johnson (JNJ) Hits New 52-Week High on Strong Earnings

    Jul 19, 2016 | American Banking and Market News

    Johnson & Johnson (NYSE:JNJ) shares hit a new 52-week high on Tuesday following a stronger than expected earnings report. The company traded as high as $125.75 and last traded at $125.10, with a volume of 6,491,292 shares trading hands. The stock had previously closed at $123.14.

    The company reported $1.74 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.69 by $0.05. The firm had revenue of $18.50 billion for the quarter, compared to analysts’ expectations of $17.98 billion.

    The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $0.80 dividend. The ex-dividend date of this dividend is Friday, August 19th. This represents a $3.20 dividend on an annualized basis and a yield of 2.60%.

    A number of research analysts have commented on the stock. JPMorgan Chase & Co. restated a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, April 17th. Royal Bank Of Canada restated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, April 17th. BTIG Research restated a “hold” rating on shares of Johnson & Johnson in a research note on Sunday, May 22nd. Leerink Swann restated a “buy” rating on shares of Johnson & Johnson in a research note on Sunday, May 22nd. Finally, Deutsche Bank AG restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, April 6th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $112.77.

    In other Johnson & Johnson news, CAO Ronald A. Kapusta sold 3,957 shares of the business’s stock in a transaction on Tuesday, May 10th. The shares were sold at an average price of $114.77, for a total value of $454,144.89. Following the sale, the chief accounting officer now owns 29,682 shares of the company’s stock, valued at approximately $3,406,603.14. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Gary J. Pruden sold 9,735 shares of the business’s stock in a transaction on Tuesday, June 7th. The shares were sold at an average price of $116.03, for a total transaction of $1,129,552.05. Following the completion of the sale, the vice president now directly owns 43,630 shares in the company, valued at approximately $5,062,388.90. The disclosure for this sale can be found here.

    Other large investors have made changes to their positions in the company. Heritage Wealth Advisors raised its stake in shares of Johnson & Johnson by 3.3% in the fourth quarter. Heritage Wealth Advisors now owns 9,944 shares of the company’s stock valued at $1,021,000 after buying an additional 317 shares during the period. Lourd Capital LLC raised its stake in shares of Johnson & Johnson by 8.3% in the fourth quarter. Lourd Capital LLC now owns 11,115 shares of the company’s stock valued at $1,142,000 after buying an additional 851 shares during the period. Eidelman Virant Capital raised its stake in shares of Johnson & Johnson by 11.8% in the fourth quarter. Eidelman Virant Capital now owns 11,623 shares of the company’s stock valued at $1,193,000 after buying an additional 1,231 shares during the period. Wedgewood Investors Inc. PA raised its stake in shares of Johnson & Johnson by 0.4% in the fourth quarter. Wedgewood Investors Inc. PA now owns 11,883 shares of the company’s stock valued at $1,221,000 after buying an additional 50 shares during the period. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Johnson & Johnson by 9.9% in the fourth quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 13,032 shares of the company’s stock valued at $1,339,000 after buying an additional 1,179 shares during the period.

    The stock’s 50 day moving average is $118.41 and its 200 day moving average is $109.83. The firm has a market cap of $344.13 billion and a PE ratio of 22.80.

    Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

     

    Return to headline | Return to top

35. Can Johnson & Johnson Keep Soaring Higher?

    Jul 20, 2016 | TheStreet

    By Gary Morrow

    Shares of Johnson & Johnson  ( JNJ) reached new all-time highs yesterday with the help of a 1.7% surge. This earnings-inspired rally extends the stock's powerful post-Brexit rebound to just over 8.5%. There's no question that Johnson & Johnson is hitting on all cylinders, but further upside in the near term could be quite limited. For patient investors, it may prove wise to wait out a healthy pullback before jumping on the Johnson & Johnson train.

    Johnson & Johnson has been tracing out an almost completely uninterrupted rally since the mid-January low. This impressive performance includes six straight higher monthly highs as shares moved past the 2014 and 2015 peaks. Since April 15, Johnson & Johnson has been pushing further into new all-time-high territory while remaining below overbought conditions based on its daily moving average convergence/divergence indicator. In fact, just prior to Johnson & Johnson's early June breakout, the MACD had returned to neutral. Of late, though, this setup has changed. Both the daily and weekly MACD indicators have reached extremes. As measured by the weekly MACD, Johnson & Johnson has never been more overbought. 

    While there's no doubt that Johnson & Johnson still has a great deal of momentum in place following Tuesday's surge, big gains from current levels are unlikely. A shallow pullback may be all that's needed to relieve enough pressure for the rally to resume. If Johnson & Johson begins to roll over, the June high near $121.40 will prove to be a key level. This is the initial support area, but a break below here could gather steam quickly considering the extreme overbought reading. 

    Once through the June low, a retest of the 50-day moving average is the next target. A pullback to this area, just above $117, would offer a low-risk entry opportunity for patient investors.

    Return to headline | Return to top

36. Johnson & Johnson (JNJ) Broke Out To A New High After Q2 Earnings Beat

    Jul 20, 2016 | RTT News

    Johnson & Johnson (JNJ) reported second quarter adjusted EPS of $1.74 Tuesday morning, up from $1.71 last year. Analysts expected EPS of $1.68. The company also increased its full year adjusted EPS forecast to between $6.63 and $6.73, from prior expectations of $6.53 to $6.68. Street expectations are for EPS of $6.61.

    Johnson & Johnson gapped up sharply Tuesday, but traded in a range for the majority of the session. The stock closed higher by 2.11 at $125.25 on above average volume. Johnson & Johnson climbed above a 2-week trading range and set a new high for the year.

    Return to headline | Return to top

37. Johnson & Johnson Boosts Dow, Netflix Pressures the S&P 500

    Jul 20, 2016 | Keris Alison Lahiff

    By Keris Alison Lahiff

    It was the tale of two earnings seasons on Tuesday and Wall Street was stuck in the middle.

    While better-than-expected earnings from Johnson & Johnson pushed the Dow Jones Industrial Average to close out the day with another record, disappointment over Netflix pushed the S&P 500 and Nasdaq into the red.

    The S&P 500 was down 0.14%, and the Nasdaq slid 0.4%. The Dow added 0.14% to settle at 18,559, a record close.

    Around one-tenth of S&P 500 companies have reported so far this season in what is expected to be another three-month period of shrinking earnings. The blended earnings estimate is expected to decline 4.3%, a slower decline than 5% in the first quarter.

    Netflix dominated headlines after falling short of analysts' estimates for subscriber numbers, a closely watched metric. The streaming service added 1.7 million international subscribers in its recent quarter, below its own forecast of 2.5 million. Earnings came in above estimates, though.

    Johnson & Johnson , meanwhile, was one of the best performers on the Dow after topping estimates in its second quarter and raising its full-year forecasts. A new line of pharmaceutical products helped to boost growth, overshadowing a slide in sales in its consumer health business.

    A rebound in bond-trading activity helped Goldman Sachssurpass Wall Street earnings expectations. Finance companies with investment businesses like Goldman have benefited from second-quarter rallies in deal-making and initial public offerings during the second quarter.

    Crude oil also pressured markets Tuesday ahead of a weekly reading on inventories from the American Petroleum Institute out after the bell and an official read from the Energy Information Administration mid-morning Wednesday. Ballooning global supplies and production have pummeled crude prices since last year.

    West Texas Intermediate crude oil closed down 1.3% at $44.65 a barrel on Tuesday afternoon.

    "The price of oil has come down on over-supply fears from OPEC producers, despite improving economic data from the U.S. and China," Peter Cardillo, chief market economist at First Standard Financial, wrote in a note. "The price movement has challenged the lower end of our trading range under $47. However, prices have not slipped to levels that would suggest a renewed downward trend is about to unfold."

    Monsanto rebuffed a sweetened offer from Bayer on Tuesday, though said it was open to further discussions with the chemical company and others interested in M&A talk. Bayer had raised its offer to $125 a share from $122 a share last Thursday in an all-cash bid.

    Housing starts in June climbed, the Commerce Department said on Tuesday, driven by a high level of demand and tight inventory. Starts for newly constructed homes rose 4.8% last month to an adjusted annual pace of 1.19 million. Economists had expected a pace of 1.17 million. May's numbers were revised down to 1.14 million from 1.16 million. Housing permits increased 1.5% to 1.15 million.

    "The overall tone of this report was encouraging, pointing to further upside momentum in U.S. housing market activity," said Millan Mulraine, deputy chief U.S. macro strategist at TD Securities. "The buoyancy in both construction activity and building intentions speaks to the renewed level of confidence among U.S. homebuilders about the outlook for this sector, and we continue to expect the recovery in this segment of the US economy to remain on track in the coming months."

    Return to headline | Return to top

38. Johnson & Johnson Hits Record High Despite Declines in Baby Care

    Jul 19, 2016 | TheStreet

    By Alicia McElhaney

    Johnson & Johnson share prices reached new heights Tuesday morning after reporting better-than-expected second quarter earnings.

    Shares in the pharmaceutical company, which has a market cap of $343.7 billion, hit $127, an all time high, in pre-opening trading Tuesday, after its reported earnings per share of $1.74 beat Wall Street's consensus estimate by six cents. The stock fell back to $124.93 by midday, though it was still up approximately 1% from the market's open.

    Sales for the second quarter were up 2.3%, from to $36 million from $35.2 billion from the same period in 2015. Sales in the U.S. rose at more than three times that clip, at 7.4%.

    "Johnson & Johnson delivered another strong pharmaceutical quarter," analyst Glenn Novarro of RBC Capital Markets said. "When pharmaceuticals perform well the stock performs well."

    Not all segments saw growth, however. Baby care, for one, saw yet another slump in sales, to $102 million in the second quarter of 2016 from $104 million for last year's second quarter.

    Alex Gorsky, CEO of Johnson & Johnson, conceded as much during Tuesday morning's earnings call, noting that the company needs to improve in its baby care segments and make further inroads in China.

    Gorsky and the other J&J executives on the call said they would stick to their current M&A strategy.

    "The M&A approach that we talked about in the past is a balanced one," Gorsky said, noting that the most of the 124 deals J&J has done in the past 14 years have been smallish.

    "We look at tuck-ins, midsize and large deals," he said. "Tuck-ins are those where we feel we can make the most value."

    In the second quarter, J&J completed five, including NeuWave Medical, BioMedical Enterprises, HIPOGLOS, NeoStrata and Vogue International.

    Gorsky added that within the medical device division, the company can look to grow, particularly in vision, including devices within eyes or surgical devices.

    However, high purchase prices could hold back further acquisitions in the near term.

    "There are some expectations that are still not normalized for appropriate valuations in the market," Dominic Caruso, chief financial officer of JNJ said during the earnings call. "That's a factor that'll take time and we're patient with that."

    Caruso also dismissed investor concerns that M&A is hamstrung because J&J holds much of its cash overseas to avoid U.S. tax.

    "Whether or not the cash is trapped overseas or not is not at all an impediment in our ability to do acquisitions," he said."We'll obviously try to find a way to do [deals] on a tax efficient basis, but we can continue to borrow to do the acquisitions."

    Jim Cramer, founder of TheStreet, saidJ&J has "such great organic growth... They have an anti-cancer franchise that's really re-rating them. That's how the stock is going."

    He noted that the company hasn't had to do what most other large cap pharmaceutical players have-acquire a biotech company-to keep up that growth.

    "This is the fastest growing pharmaceutical company other than Bristol Myers in pure drugs," Cramer said. "They just keep coming up with big drug after big drug."

    Return to headline | Return to top

39. Johnson & Johnson has reported second-quarter net income of $US4 billion

    Jul 20, 2016 | AAP

    The New Brunswick, New Jersey-based company said it had profit of $US1.43 per share. Earnings, adjusted for non-recurring costs and amortisation costs, came to $US1.74 per share.

    The results surpassed Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for earnings of $US1.67 per share.

    The world's biggest maker of healthcare products posted revenue of $US18.48 billion in the period, also topping Street forecasts. Five analysts surveyed by Zacks expected $US17.89 billion.

    Johnson & Johnson expects full-year earnings in the range of $US6.63 to $US6.73 per share, with revenue in the range of $US71.5 billion to $US72.2 billion.

    Johnson & Johnson shares have increased 20 per cent since the beginning of the year, while the Standard & Poor's 500 index has increased 6 per cent. The stock has risen 22 per cent in the last 12 months.

    Return to headline | Return to top

Television Coverage

40. CNBC Squawk Box

    Jul 19, 2016 | CNBC Squawk Box

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23502590?token=03bbf64d-6306-4800-9204-97f1989fffcd
    

    Return to headline | Return to top

41. Bloomberg Surveillance Video Clip

    Jul 19, 2016 | Bloomberg Surveillance

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23502603?token=03bbf64d-6306-4800-9204-97f1989fffcd

    (58 seconds)

    Return to headline | Return to top

42. Dominic Caruso Squawk Box Video Clip

    Jul 19, 2016 | CNBC Squawk Box

    View Clip Here: http://app.criticalmention.com/app/#/report/d58397c4-b79a-4310-9849-59492113ecbd 

    (4 minutes 34 seconds)

    Return to headline | Return to top

43. Bloomberg GO Dominic Caruso Video Clip

    Jul 19, 2016 | Bloomberg GO

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23503029?token=03bbf64d-6306-4800-9204-97f1989fffcd

    (7 minutes 11 seconds)

    Return to headline | Return to top

44. Jim Cramer Squawk on the Street Video Clip

    Jul 19, 2016 | CNBC Squawk on the Street

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23504549?token=03bbf64d-6306-4800-9204-97f1989fffcd

    (2 minutes 4 seconds)

    Return to headline | Return to top

45. Bloomberg Markets Europe Video Clip

    Jul 19, 2016 | Bloomberg Markets (Europe)

    View Clip Here: http://app.criticalmention.com/app/#clip/view/23507632?token=03bbf64d-6306-4800-9204-97f1989fffcd

    (20 seconds)

    Return to headline | Return to top

46. NJTV News With Mary Alice Williams Video Clip

    Jul 19, 2016 | NJTV News With Mary Alice Williams

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23522914?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04
    

    Return to headline | Return to top

47. Mad Money Jim Cramer Video Clip

    Jul 19, 2016 | Mad Money

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523048?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04
    

    Return to headline | Return to top

48. WNET Nightly Business Report (PBS NY) Video Clip

    Jul 19, 2016 | WNET Nightly Business Report (PBS NY)

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523119?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04
    

    Return to headline | Return to top

49. Capital Connection Video Clip

    Jul 20, 2016 | Capital Connection

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523591?token=3205c0b0-65a2-4ebd-8589-2ff56c1daa04

    Return to headline | Return to top

50. Squawk on the Street Video Clip

    Jul 20, 2016 | Squawk on the Street

    View Clip Here: http://beta.criticalmention.com/app/#clip/view/23523682?token=
    

    Return to headline | Return to top